0001493152-17-013096.txt : 20171114 0001493152-17-013096.hdr.sgml : 20171114 20171114130720 ACCESSION NUMBER: 0001493152-17-013096 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROLUNG INC CENTRAL INDEX KEY: 0001541884 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 201922768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54600 FILM NUMBER: 171200053 BUSINESS ADDRESS: STREET 1: 757 EAST SOUTH TEMPLE, SUITE 150 CITY: SALT LAKE CITY STATE: UT ZIP: 84102 BUSINESS PHONE: 801-204-9623 MAIL ADDRESS: STREET 1: 757 EAST SOUTH TEMPLE, SUITE 150 CITY: SALT LAKE CITY STATE: UT ZIP: 84102 FORMER COMPANY: FORMER CONFORMED NAME: FRESH MEDICAL LABORATORIES, INC. DATE OF NAME CHANGE: 20120209 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

[X]	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended September 30, 2017

[ ]	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from ______________ to ______________

Commission file number: 000-54600

PROLUNG, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-1922768
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

757 East South Temple, Suite 150
Salt Lake City, Utah		84102
(Address of principal executive offices)		(Zip Code)

(801) 736–0729

(Registrant’s telephone number, including area code)

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[ ]	Smaller reporting company	[X]
		Emerging growth company	[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act .. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of November 10, 2017, the issuer had 3,861,598 shares of Common Stock, $0.001 par value, outstanding.

PROLUNG, INC.

TABLE OF CONTENTS

	Part I – Financial Information	3

Item 1	Financial Statements	3

	Condensed Consolidated Balance Sheets (Unaudited), September 30, 2017 and December 31, 2016	3

	Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months Ended September 30, 2017 and 2016	4

	Condensed Consolidated Statement of Stockholders’ Equity (Deficit) (Unaudited) for the Nine Months Ended September 30, 2017	5

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2017 and 2016	6

	Notes to the Unaudited Condensed Consolidated Financial Statements	7

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3	Quantitative and Qualitative Disclosures about Market Risk	24

Item 4	Controls and Procedures	24

	Part II – Other Information	25

Item 1	Legal Proceedings	25

Item 1A	Risk Factors	25

Item 2	Unregistered Sales of Equity Securities And Use Of Proceeds	25

Item 3	Defaults Upon Senior Securities	25

Item 4	Mine Safety Disclosures	25

Item 5	Other Information	25

Item 6	Exhibits	26

Signatures		27

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ProLung, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

(Unaudited)

	September 30, 2017			December 31, 2016
Assets
Current Assets
Cash	$	1,783,449		$	28,922
Prepaid expenses		20,981			8,831
Deferred offering costs		330,960			-
Total Current Assets		2,135,390			37,753

Inventory, noncurrent		314,465			291,559
Property and equipment, net of accumulated depreciation		84,651			82,917
Intangible assets, net of accumulated amortization		158,567			165,738

Total Assets	$	2,693,073		$	577,967

Liabilities and Stockholders’ Equity (Deficit)
Current Liabilities
Accounts payable	$	194,957		$	358,477
Accrued liabilities		64,677			264,698
Related-party notes payable		-			105,000
Current portion of long-term debt		-			32,000
Total Current Liabilities		259,634			760,175

Long-Term Liabilities
Long-term debt, net of current portion		1,206,931			2,653,370
Total Long-Term Liabilities		1,206,931			2,653,370

Total Liabilities		1,466,565			3,413,545

Stockholders’ Equity (Deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding		-			-
Common stock, $0.001 par value; 120,000,000 shares authorized; 3,861,598 shares and 3,000,815 shares issued and outstanding, respectively		3,862			3,001
Additional paid-in capital		20,914,110			13,247,054
Accumulated deficit		(19,691,464	)		(16,085,633	)
Total Stockholders’ Equity (Deficit)		1,226,508			(2,835,578	)

Total Liabilities and Stockholders’ Equity (Deficit)	$	2,693,073		$	577,967

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ProLung, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(Unaudited)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
Revenues:
Revenue	$	-		$	-		$	-		$	-

Total revenue		-			-			-			-

Cost of revenue		-			-			-			10,193

Gross loss		-			-			-			(10,193	)

Operating expenses:
Research and development expense		274,407			241,809			1,034,934			806,052
Selling, general and administrative expense		1,067,502			360,172			2,472,250			1,065,631
Loss on disposal of property and equipment		-			-			690			-
Total operating expenses		1,341,909			601,981			3,507,874			1,871,683

Loss from operations		(1,341,909	)		(601,981	)		(3,507,874	)		(1,881,876	)

Other income (expense):
Interest expense		(24,211	)		(65,526	)		(97,957	)		(204,282	)
Total other income (expense)		(24,211	)		(65,526	)		(97,957	)		(204,282	)

Net loss	$	(1,366,120	)	$	(667,507	)	$	(3,605,831	)	$	(2,086,158	)

Basic and diluted loss per share	$	(0.35	)	$	(0.23	)	$	(1.02	)	$	(0.75	)

Weighted-average common shares outstanding, basic and diluted		3,849,791			2,870,596			3,522,810			2,793,738

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ProLung, Inc. and Subsidiary

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

For the Nine Months Ended September 30, 2017

(Unaudited)

	Common Stock				Additional Paid-in			Accumulated			Total Stockholders’ Equity
	Shares		Amount		Capital			Deficit			(Deficit)
Balance, December 31, 2016		3,000,815	$	3,001	$	13,247,054		$	(16,085,633	)	$	(2,835,578	)
Common stock issued upon conversion of debt and accrued interest		249,834		250		1,355,539			-			1,355,789
Common stock issued for cash and warrants, net of offering costs		544,300		545		6,531,022			-			6,531,567
Offering costs paid in cash		-		-		(664,452	)		-			(664,452	)
Common stock issued to placement agent		55,372		55		(55	)		-			-
Common stock issued upon conversion of related party debt and accrued interest		5,000		5		59,995			-			60,000
Issuance of common stock to consultants for services		6,250		6		53,494			-			53,500
Stock-based compensation		-		-		331,513			-			331,513
Rounding due to reverse stock split		27		-		-			-			-
Net loss		-		-		-			(3,605,831	)		(3,605,831	)
Balance, September 30, 2017		3,861,598	$	3,862	$	20,914,110		$	(19,691,464	)	$	1,226,508

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ProLung, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	For the Nine Months Ended
	September 30,
	2017			2016
Cash flows from operating activities:
Net loss	$	(3,605,831	)	$	(2,086,158	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		24,195			24,889
Stock-based compensation		385,013			332,241
Obsolete inventory		-			10,193
Loss on disposal of property and equipment		690			-
Change in assets and liabilities:
Inventory		(22,906	)		(162,379	)
Prepaid expenses		(12,150	)		26,964
Accounts payable		(163,520	)		230,306
Accrued liabilities		(32,282	)		169,430
Net cash flows from operating activities		(3,426,791	)		(1,454,514	)

Cash flows from investing activities:
Payments for property and equipment		(19,842	)		-
Proceeds from sale of property and equipment		394			-
Net cash flows from investing activities		(19,448	)		-

Cash flows from financing activities:
Offering and deferred offering costs paid in cash		(995,412	)		-
Issuance of common stock and warrants for cash		6,531,567			882,224
Payments on convertible debenture		(164,000	)
Proceeds from notes payable		-			32,000
Payments on notes payable		(121,389	)		-
Proceeds from related party debt		-			185,000
Payments on related party notes payable		(50,000	)		(55,000	)
Net cash flows from financing activities		5,200,766			1,044,224

Net increase (decrease) in cash		1,754,527			(410,290	)
Cash at beginning of period		28,922			451,526
Cash at end of period	$	1,783,449		$	41,236

Supplemental disclosure of cash flow information:
Cash paid for interest	$	169,623		$	48,744
Cash paid for income taxes	$	-		$	-

Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible debt and interest	$	1,255,789		$	785,167
Partial conversion of debt to equity	$	100,000		$	-
Extinguishment of related-party note and interest with common stock	$	60,000		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1 – Organization and Summary of Significant Accounting Policies

Organization

ProLung, Inc. (formerly Fresh Medical Laboratories, Inc.) (the “Company”) is a Delaware corporation that was incorporated on November 22, 2004. The Company’s headquarters are located in Salt Lake City, Utah. The Company’s business is the development, marketing, and sale of precision predictive analytical medical devices specializing in lung cancer. The Company’s principal activities are primarily developing markets for its products, securing strategic alliances and obtaining financing.

Principles of Consolidation

During the year ended December 31, 2012, the Company formed a wholly-owned subsidiary, Hilltop Acquisition Corporation, Inc., which has had no activity since its inception and is included in the accompanying condensed consolidated financial statements from the date of its formation.

Reverse Stock Split

On October 10, 2017, the Company’s Board of Directors approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effectuate a 1-for-8 reclassification, or reverse stock split, of the Company’s common stock, to be effective as of October 25, 2017. All share, option, warrant, per share, per option and per warrant amounts in the condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to the reverse stock split.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared by management in accordance with rules and regulations promulgated by the U.S. Securities and Exchange Commission and therefore certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments necessary for them to be presented fairly, with those adjustments consisting only of normal recurring adjustments. These interim financial statements should be read in conjunction with the Company’s consolidated financial statements as of, and for the year ended, December 31, 2016 included in the Company’s Amendment No. 3 to the Annual Report on Form 10-K for the year ended December 31, 2016. The results of operations for the three and nine months ended September 30, 2017 may not be indicative of the results to be expected for the year ending December 31, 2017.

The Company has incurred losses since inception while pursuing the development of its primary predictive analytical medical device, and approval from the U.S. Food and Drug Administration (“FDA”) to market the device, while also developing markets outside the United States. The Company incurred net losses of $3.6 million and $2.1 million for the nine months ended September 30, 2017 and 2016, respectively. Cash used in operating activities was $3.4 million and $1.5 million for the nine months ended September 30, 2017 and 2016, respectively. Historically, operations have been funded primarily through the sale of equity or debt securities. Should management continue to fund operations at similar levels, additional equity or debt securities would need to be sold, or other financing arrangements made.

The Company has the ability to maintain current levels of spending, or reduce expenditures significantly if funding is not available. Additionally, should FDA approval be obtained, the Company could execute on an aggressive marketing plan that would require significant additional funding; however, this plan would not begin until funding is in place.

Basic and Diluted Loss Per Share

The Company computes basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. The Company computes diluted loss per share by dividing net loss by the sum of the weighted-average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of diluted loss per share does not assume exercise or conversion of securities that would have an anti-dilutive effect. As of September 30, 2017, and 2016, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

	For the Three and Nine Months Ended
	September 30,
	2017		2016
Warrants to purchase shares		1,205,623		177,901
Stock options		127,500		-
Non-vested shares		-		1,359
Convertible debentures		-		275,509
Convertible notes		201,155		205,212

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was amended with ASU No. 2015-14, ASU No. 2016-08, ASU No. 2016-10, ASU No. 2016-12 and ASU No. 2016-20. These new standards supersede all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The Company is evaluating the guidance but does not at this time expect it to have a material impact on the Company’s revenue recognition. However, the Company does expect to have significant changes to the footnote disclosures related to revenue recognition as a result of implementing these new standards. As the Company is an emerging growth company, this standard will be implemented effective January 1, 2019.

In February 2016, the FASB issued ASU No. 2016-02: Leases ASU 2016-02 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. ASU 2016-02 will be effective for the Company’s fiscal year beginning January 1, 2019, on a modified retrospective basis and earlier adoption is permitted. Management is currently evaluating the impact of the pending adoption of ASU 2016-02 on the Company’s consolidated financial statements.

In November 2016, the FASB issued an ASU amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt this ASU on January 1, 2018 and does not expect any accounting significance upon adoption.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. This Standard was issued to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt this ASU on January 1, 2018, since this standard is to be applied prospectively there will be no effect on prior financial statements and the Company does not currently have plans where this standard would be applicable.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II). Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down round features. Part II simply replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within Accounting Standards Codification (ASC) Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. This ASU is effective for public companies for the annual reporting periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of the standard may have on its consolidated financial statements and does not anticipate early adopting.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities was issued in August 2017. The amendments under ASU 2017-12 refine and expand hedge accounting requirements for both financial (e.g., interest rate) and commodity risks. Its provisions create more transparency around how economic results are presented, both on the face of the financial statements and in the footnotes. It also makes certain targeted improvements to simplify the application of hedge accounting guidance. ASU 2017-12 becomes effective for the Company in the first quarter of 2019. The Company is currently assessing the impact the adoption of this ASU will have on the consolidated financial statements.

Note 2 – Inventory

Inventory consists of the following:

	September 30, 2017			December 31, 2016

Raw materials	$	66,846		$	69,264
Work in progress		11,222			31,185
Finished goods		236,397			191,110

Total inventory		314,465			291,559
Less carrying value of inventory not deemed to be a current asset		(314,465	)		(291,559	)

Inventory, included in current assets	$	-		$	-

Note 3 – Accrued Liabilities

Accrued liabilities consisted of the following at September 30, 2017 and December 31, 2016:

	September 30, 2017		December 31, 2016
Accrued interest	$	-	$	234,405
Accrued royalties		17,873		17,873
Accrued payroll and payroll taxes		46,804		12,420

Total accrued liabilities	$	64,677	$	264,698

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 4 –Short and Long-term Debt

Short and Long-term debt is summarized as follows

	September 30, 2017		December 31, 2016

Convertible debentures; unsecured; interest at 8.00% per annum; settled during 2017	$	-	$	1,257,050

Convertible notes payable; unsecured; interest at 8.00% per annum; due November 6, 2020		1,206,931		1,206,931

Note payable secured by all the assets of the Company; interest at 15.00% per annum; settled during 2017		-		189,389

Related-party note payable; interest at 8%; settled during 2017		-		105,000

Unsecured note payable; interest at 10.00% per annum; settled during 2017		-		32,000

Total long-term debt		1,206,931		2,790,370

Less: current portion		-		137,000

Long-term debt, net of current portion	$	1,206,931	$	2,653,370

Convertible Debentures

During the nine months ended September 30, 2017 convertible debentures were converted or repaid as follows: The Company repaid $164,000 in principal along with $25,700 in related accrued interest. The remaining convertible debenture holders elected to convert $1,093,050 in principal along with $162,739 in related interest into 241,500 shares of common stock at a rate of $5.20 per share.

As further described in Note 5 to these unaudited condensed consolidated financial statements, the Company entered into placement agent agreements that provide for compensation to the respective placement agent in connection with an offering of common stock. Additionally, the placement agent agreements provide for potential compensation to the placement agent in connection with the future conversion of the convertible debentures into shares of common stock of the Company. Upon the conversion of the convertible debentures, the Company was required to issue the placement agent warrants to acquire shares of the Company’s common stock at an exercise price of $5.20 per share. The placement agent will be issued a warrant to purchase one share of common stock for each $6.48 of the principal amount of the convertible debentures converted into common stock, with the maximum number of warrants issuable under the Placement Agreement limited to 330,433 shares of the Company’s common stock. The term of the warrants is for a period of 36 months from the date of issuance. During the nine months ended September 30, 2017, 330,425 warrants were issued to then-current placement agent.

Convertible Notes Payable

In 2015, the Company issued two convertible promissory notes (the “convertible notes”) in the aggregate principal amount of $1,206,931 to two investment entities controlled by a single family. The convertible notes are unsecured and accrue interest at the rate of 8% per annum, with interest payable on the last day of each calendar quarter. The principal amount under the convertible notes is due on the five-year anniversary of the issue date. The convertible notes are convertible at any time prior to maturity at the option of the holders at a conversion rate of $6.00 per share. If the Company’s common stock commences trading and closes at a price of $28.00 per share for five consecutive trading days, the principal amount under the convertible notes automatically converts into common stock at the rate of $6.00 per share.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note Payable to a Relative of an Executive Officer

During the nine months ended September 30, 2017, $89,389 of principal of a master note to an individual related to an executive officer of the Company was repaid along with interest of $39,071. In addition, the noteholder elected to convert the remaining $100,000 of principal for 8,334 shares of common stock as well as 8,334 warrants to purchase stock at a price of $12.00 per unit.

Other Notes Payable

During the nine months ended September 30, 2017, the Company repaid $32,000 of principal along with $1,185 of related accrued interest. These proceeds were received during the nine months ended September 30, 2016.

Related-Party Note payable

During the nine months ended September 30, 2017, $105,000 of principal of related-party notes was repaid along with interest and fees of $5,000. $55,000 of this principal and the related interest was settled in common stock and $50,000 was settled in cash. The related party elected to convert $60,000 of principal and interest into 5,000 shares, as well as 5,000 warrants to purchase stock, at a price of $12.00 per unit.

During the nine months ended September 30, 2016, the Company issued notes to a related-party for $185,000. Also during the nine months ended September 30, 2016, $55,000 of the related-party notes were paid back along with interest and fees of $599.

Note 5 – Common Stock

Increase in Authorized Shares

In July, 2017, following the receipt of board authorization and stockholder approval, the Company filed an Amended and Restated Certificate of Incorporation which, among other things, increased the authorized number of shares of common stock from 40,000,000 shares to 120,000,000. The increase in authorized shares has been reflected on the Company’s condensed consolidated balance sheet.

Public Offering of Common Stock of the Company

On August 4, 2017, the Company filed a Registration Statement on Form S-1 (as modified from time to time, the “Registration Statement”), to which it filed a pre-effective amendment on October 17, 2017. This Registration Statement relates to a potential public offering of the Company’s common stock. Such Registration Statement is subject to review before it becomes effective. There is no assurance that any shares will be offered and sold pursuant to such Registration Statement. During the nine months ended September 30, 2017, the Company has incurred cash offering costs totaling $330,960 which will be offset against the proceeds received, if such offering is completed. If the Company does not complete the offering, the deferred offering costs will be charged to expense.

Private Placement of Common Stock of the Company

The Company has been issuing equity under a private placement agreement. The Company offered a minimum of 41,667 units, comprised of one share of common stock and one warrant to purchase one share of common stock at $12.00, or a maximum of 437,500 units at a purchase price of $12.00 per unit, for a minimum offering amount of $500,000 and a maximum offering amount of $5,250,000, which maximum amount was increased to 682,669 units, and $8.2 million by the Board of Directors in February 2017. The units were offered to a limited number of prospective investors who qualify as “accredited investors.” The units were offered on a “best efforts, all-or-none” basis for the first 41,667 units subscribed for and on a “best efforts” basis thereafter.

The Company engaged two separate placement agents during different time periods in connection with the offering, which placement agents were entitled to a cash commission of ten percent of the issuance price of the common stock sold in the offering, and one share of common stock of the Company for each ten shares of the Company’s common stock sold in the offering. Pursuant to these agreements, the Company had incurred commission fees to the placement agents of $826,146 together with 68,268 shares of common stock as of September 30, 2017. For the nine months ended September 30, 2017, the Company received subscriptions for $6,531,567 and paid $664,452 in offering costs.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

During the nine months ended September 30, 2016, 82,380 shares were subscribed, conditions for the minimum offering were met, and the Company received net proceeds of $882,224 from the offering.

As of September 30, 2017, the adjusted maximum offering amount of $8.2 million was subscribed for and the offering was closed.

Common Stock Issued for Conversion of Convertible Debentures and Notes Payable

During the nine months ended September 30, 2017, $1,093,050 of convertible debentures and $162,739 of accrued interest was converted at $5.20 per share into 241,500 shares of common stock. As partial settlement of a note payable to a relative of an executive officer, $100,000 was converted at $12.00 per share into 8,334 shares of common stock. Also, in partial settlement of a related party note, $55,000 of principal and $5,000 of interest was converted at $12.00 per share into 5,000 shares of common stock.

During the nine months ended September 30, 2016, certain convertible debenture holders exercised their right and converted $717,950 of principal and $67,217 of accrued interest into common stock. The Company issued 150,994 shares of common stock at $5.20 per share.

Common Stock Issued for Services

In addition, during the nine months ended September 30, 2016, the Company issued 2,496 shares of common stock with a total value of $29,651 to two consultants for services rendered.

The Company recognized stock-based compensation related to the shares issued to directors, officers and consultants for the nine months ended September 30, 2017 and 2016 of $53,500 and $332,241, respectively.

Periodically, the Company issues non-vested common stock to directors, officers and consultants as compensation for future services. During the nine months ended September 30, 2017 and 2016, the Company recognized $433 and $121,400 in stock compensation expense related to the amortization of this deferred compensation.

A summary of the status of the Company’s restricted common stock grants as of September 30, 2017 and changes during the nine months then ended, is presented below:

	Restricted			Weighted
	Common			Average
	Stock			Common
	Grants			Stock Price

Balance at December 31, 2016		109		$	4.00
Awarded		-			-
Vested		(109	)		4.00

Balance at September 30, 2017		-

As of September 30, 2017, there are no longer any restricted common stock grants.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Total stock-based compensation expense from all sources for the three and nine months ended September 30, 2017 and 2016, including stock-based compensation for the options and warrants discussed in Note 6 and 7, has been included in the unaudited condensed consolidated statements of operations as follows:

	For the Three Months Ended				For the Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016

Research and development expense	$	-	$	79,915	$	-	$	227,392
Selling, general and administrative expense		261,153		30,854		385,013		104,849

Total share-based compensation	$	261,153	$	110,769	$	385,013	$	332,241

Note 6 – Common Stock Options

Equity Incentive Plan

In April 2017 the Board of Directors, contingent on shareholder approval, approved the ProLung Inc. Stock Incentive Plan (the “Plan”). The shareholders approved the Plan in July 2017. The Plan authorizes the Board Compensation Committee to grant incentive stock options, non-incentive stock options, stock bonuses, restricted stock, and performance-based awards to directors, officers and employees and non-employee agents, consultants, advisers and independent contractors of the Company or any parent or subsidiary of the Company.

The total number of initial shares of Common Stock authorized for issuance under the Plan is 500,000 shares; the authorized shares will automatically increase on January 1st of each year, for ten consecutive years, commencing on January 1, 2018, by the lesser of (i) 40,000 shares of Common Stock (i.e., 8% of the shares of the shares originally authorized to be issued), or (ii) such number of shares of common stock (if any) the Board may earlier designate in writing. If the automatic increases are not limited by the Board, there will be 900,000 shares of common stock authorized under the Plan in January 1, 2027.

Issuance of Stock Options under the Plan

Board Option Grants

In August 2017, the Board’s Compensation Committee approved the issuance of 52,500 options to Directors of the Company at exercise prices ranging from $8.00 to $10.00 per option. One half of the options (26,250) vest immediately with the remaining half (26,250) vesting quarterly through August 2018. The fair value of these options was $5.97 per option or $313,419 and will be expensed over the relative vesting period. The fair value was computed using the Black Scholes method using the following weighted-average assumptions:

Expected life	5.12 years
Exercise price	$8.33
Expected volatility	124%
Expected dividends	None
Risk-free interest rate	1.84%

The Company recorded an expense of $217,592 for the three and nine months ended September 30, 2017. The $95,827 remaining unrecognized expense will be recognized through April 2018.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

CEO Stock Option Incentive

In an amendment to the employment agreement of the CEO executed March 29, 2017 the Company agreed to grant the CEO stock option incentives related to FDA approval. The stock option shall expire 10-years after the grant date and shall vest with respect to a number of options of Common Stock upon the receipt of FDA Approval (as defined below), with such number of options to be as follows:

●	150,000 options if FDA Approval is obtained on or before January 1, 2018;

●	112,500 options if FDA Approval is obtained after January 1, 2018 and on or before July 1, 2018;

●	75,000 options if FDA Approval is obtained after July 1, 2018 and on or before January 1, 2019;

●	37,500 options if FDA Approval is obtained after January 1, 2019 and on or before January 1, 2020.

On August 9, 2017, the Compensation Committee of the Board of Directors granted the stock option described above at an exercise price of $8.00 per option. The Company considers these options to be performance based and August 9, 2017 to be the grant date. Solely for accounting purposes, the Company estimated the conditions for vesting will be met between July and December 2018. Based on this estimate, management also believes the most probable number of options to be issued will be 75,000. The Company valued these 75,000 options as of August 9, 2017 using the Black-Scholes Pricing Model using the following assumptions:

Expected life	5.75 years
Exercise price	$8.00
Expected volatility	124%
Expected dividends	None
Risk-free interest rate	1.84%

The resulting expense of $472,000 will be amortized over the estimated service period which will be the grant date through December 31, 2018. For the three and nine months ended September 30, 2017, $40,202 of expense has been recorded.

As of September 30, 2017, there are currently 297,500 options available for issuance under the Plan. As noted above we have issued performance based options to our CEO, whereby we could issue up to 150,000 options; which are included in the above options available for issuance under the Plan.

A summary of option activity for the nine months ended September 30, 2017 is presented below:

					Weighted
			Weighted		Average		Aggregate
	Options		Average		Remaining		Intrinsic
	Issued		Exercise		Contractual		Value of
	Agreements		Price		Life		Options

Outstanding at December 31, 2016		-	$	-		-	$	-
Issued		127,500		8.14		9.9 years		-
Exercised		-		-				-
Expired		-		-				-

Outstanding at September 30, 2017	$	127,500	$	8.14		9.9 years	$	-

Exercisable at September 30, 2017		32,813	$	8.53		9.9 years	$	-

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 7 – Common Stock Warrants

The Company has issued warrants to purchase its common stock for payment of consulting services, in connection with the extension of a note payable, as incentives to investors, and for cash. The fair value of warrants issued for consulting services is recognized as consulting expense at the date the warrants become exercisable. The Company values non-vested warrants utilizing the Black Scholes Method and records compensation over the requisite service period which is usually the vesting period. The fair value of warrants was estimated using the Black-Scholes option pricing model. The fair value of the warrants that vested during the nine months ended September 30, 2017 was $6.32 per warrant. The weighted-average assumptions used for the warrants that vested during the nine months ended September 30, 2017 were risk-free interest rate of 1.84%, expected volatility of 122%, expected life of 4.5 years, and expected dividend yield of zero. The fair value of the warrants that vested during the year ended December 31, 2016 was $6.08 per warrant. The weighted-average assumptions used for the warrants that vested during the year ended December 31, 2016 were risk-free interest rate of 1.33%, expected volatility of 124%, expected life of 4.5 years, and expected dividend yield of zero. The Company recognized $70,360 and $67,945 as share-based compensation and additional paid-in capital related to the vesting of warrants for the nine months ended September 30, 2017 and 2016 respectively. The Company recognized $35,446 and $33,912 as share-based compensation related to the vesting of warrants for the three months ended September 30, 2017 and 2016, respectively.

In September 2017, the Company issued 1,250 warrants to a consultant for investor relation services rendered. The warrants have an exercise price of $12 per warrant, vest immediately and expire in September 2020. The fair value of these warrants was $2,926 or $2.34 per warrant and was immediately recognized as an expense. The fair value was computed using the Black Scholes method using the following assumptions.

Expected life	1.52 years
Exercise price	$12.00
Expected volatility	107%
Expected dividends	None
Risk-free interest rate	1.33%

A summary of warrant activity for the nine months ended September 30, 2017 is presented below:

					Weighted		Aggregate
			Weighted		Average		Intrinsic
	Shares		Average		Remaining		Value of
	Under		Exercise		Contractual		Vested
	Warrants		Price		Life		Warrants

Outstanding at December 31, 2016		430,938	$	7.04		4.2 years	$	546,333
Issued		774,685		10.11		2.2 years		-
Exercised		-		-
Expired		-		-

Outstanding at September 30, 2017		1,205,623	$	9.00		2.8 years	$	1,230,829

The intrinsic value at September 30, 2017 is calculated at $7.28 per share less the exercise price, based on the management’s latest estimate of the fair value of the shares of common stock, which is the latest price the Company issued shares of common stock for cash.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 8 – Commitments and Contingencies

Consulting Representation Agreement

In February 2017, the Company entered into a consulting agreement with Dr. Robin Smith, who is a director of the Company. Under the agreement, Dr. Smith has agreed to provide advisory services related to the Company’s clinical assets, capital markets, public company related issues and other matters as agreed to by the parties. The agreement expires in November. Dr. Smith is to receive total compensation of $90,000 and received 3,750 shares of common stock.

Lease Agreement –Monthly rental payments as of September 30, 2017 are $4,140 per month through January 2019. If the Company exercises the option to renew the lease, the monthly rental payments will further escalate by 3% per year during the additional term.

Minimum lease commitments at September 30, 2017 for the remaining term of the lease are as follows:

Year ending September 30,
2018	$	41,400
Thereafter		-

Total	$	41,400

Lease expense charged to operations related to this agreement for the nine months ended September 30, 2017 and 2016 was $35,997 and $34,917, respectively.

License Agreement – The Company has a license agreement with a party related through a shareholder and former member of the board of directors. Under the agreement, the Company has the right to the exclusive use of certain patents pending and related technology in its medical devices and other products for an indefinite term. At September 30, 2017 and December 31, 2016, accrued royalties under this license agreement total $17,873, respectively.

Note 9 – Other Related Party Transactions

During the nine months ended September 30, 2017, the Company had a consulting agreement in place with one member and one former member (currently an officer of the Company) of its board of directors. The director and former director provide medical advisory services. The consulting agreement may be terminated by either the Company or by the consultant at any time and for any reason. During the three and nine months ended September 30, 2017, these individuals were paid a total of $73,761 and $153,681, respectively. During the three and nine months ended September 30, 2016, amounts paid for consulting agreements to former directors was $113,000 and $348,000, respectively.

Note 10 – Subsequent Events

On November 10, 2017, the Board’s Compensation Committee approved the issuance of 204,250 options to certain key employees. These options have an exercise price of $8.00 per option and vest quarterly over two years.

The Company evaluated all subsequent events that occurred after the balance sheet date through November 14, 2017, the date its financial statements were available to be issued, and concluded there were no additional events or transactions occurring during this period that required recognition or disclosure in the financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q (this “Report”) and the Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Form 10-K”) of ProLung, Inc. (the “Company”).

The statements contained in this Report that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should” and “would,” as well as similar expressions, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward looking. The forward-looking statements contained in this prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties, or assumptions, many of which are beyond our control that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause these differences include the following:.

	●	we are a development stage company with limited revenue and no assurance of earning significant revenue over the long term;

	●	our future success may be dependent upon additional financings to fund our operations, particularly if we obtain approval from the U.S. Food and Drug Administration (the “FDA”) to market our non-invasive lung cancer risk stratification test (the “Electro Pulmonary Nodule Scan” or “ProLung Test”), if we fail to obtain such capital, which may become more difficult if we do not receive FDA approval, we may be unable to continue as a going concern;

	●	our clinical studies may produce unfavorable results which could prevent or delay ProLung from obtaining FDA and other regulatory approvals;

	●	we must obtain regulatory approval in the US and other non-European Union markets to be able to commence marketing and sales in those markets;

	●	if we obtain FDA approval, we will be subject to Medical Device Reporting, or MDR, requirements, which may lead to inquiries, injunctions or liabilities;

	●	we offer and sell a single testing product;

	●	we may eventually want to expand the ProLung Test to other cancer targets. ProLung does not have clinical data suggesting that the ProLung Test is effective in other cancers and the ProLung Test may not be effective in other cancers;

	●	we are a small company and may be unable to compete with competitive technologies;

	●	we may be unable to protect our intellectual property rights, which are important to the potential value of our products and company;

	●	we may incur significant costs and liability if we infringe, or are accused of infringing on, the intellectual property rights of others;

	●	although we are capable of internally manufacturing to meet foreseeable demand, we may at some time be dependent upon contract manufacturers to safely and timely manufacture our products;

	●	ProLung clinical study designs have not been reviewed by the FDA; and

	●	our ProLung Test may produce false positive and false negative results; and

	●	other factors discussed in our 2016 Form 10-K.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Overview

In this Report, ProLung, Inc. (formerly Fresh Medical Laboratories, Inc.) and its consolidated subsidiary are referred to as “ProLung” in addition to as the “Company” versions of “we” or “us.” We have registered trademarks under ProLungdx®, Fresh Medical Laboratories®, ProLung®, EPN Scan®, Electro Pulmonary Nodule Scanner® and EPN Scanner®. Any other trademarks and service marks used in this Report are the property of their respective holders.

We are a medical device company that is developing, testing and commercializing its non-invasive lung cancer risk stratification test or ProLung Test. The ProLung Test was developed to be adjunctive to Computed Tomography (“CT”), or what is commonly referred to as a “CT scan” of the chest. The ProLung Test is designed to assist in evaluating the risk associated with a CT finding in the lung that is suspicious for cancer.

We believe the ProLung Test is the only predictive analytic focused on the lung. ProLung’s bioconductance technology is the first accurate and reliable “mass averaging” bioconductance device that has shown utility to evaluate the risk of lung cancer in patients with lesions of the lung in well-controlled clinical trials. The novel “mass averaging” bioconductance technology of the Company refers to the simultaneous consideration of multiple measurement pathways.

Subject to FDA approval, the ProLung Test will be introduced to the market like a standard predictive analytic test without the need for transmission of a physical sample or specimen. Instead, the ProLung Test acquires precision bioconductance measurements by means of a patented Probe and disposable diaphoretic electrodes placed on the back and arms. The data containing precision measurements is processed by a proprietary classified algorithm, and a report is electronically generated that may be used by the physician, in addition to other risk factors such as nodule size, family history, gender, histology and other risk stratification information, to evaluate patients with suspicious masses or lesions identified by the CT scan. The ProLung Test is immediate, pain-free, non-invasive, and non-radiating. It requires little patient preparation and can be completed in less than 30 minutes by a proficient technician.

When patients at high risk of lung cancer have suspicious lung findings after CT evaluation, clarifying the risk of the disease, or risk stratification, has the potential to reduce the cost, anxiety, and/or time associated with the inaccurate and/or delayed diagnosis of lung cancer. Risk stratification may also play a role in identifying those patients who need to modulate the extent and frequency of follow-up. On December 31, 2013, the U.S. Preventative Services Task Force recommended CT screening guidelines for lung cancer in adults aged 55 to 80 who have a 30 pack-year history and currently smoke or have quit smoking in the past 15 years. On February 5, 2016, Medicare began to pay for lung cancer screening. The guideline and its related reimbursement by Medicare are expected to increase the number of individuals identified with suspicious findings in the lung that may be candidates for the ProLung Test. The reimbursement also expected to increase the development of lung cancer centers for interdisciplinary review of screening results. We believe that these changes may increase the number of patients seeking further risk assessment from the administrations of tests like the ProLung Test.

On May 10, 2013, the ProLung Test received the “CE” mark in Europe for its Electro Pulmonary Nodule Scanner. This marking is regulatory approval that clears the marketing and sales of the ProLung Test in the European Economic Area and European Free Trade Association Countries representing 509 million individuals and 31-member states. The new screening guidelines and Medicare coverage announced in the U.S. for lung cancer screening are not available in Europe.

In the United States, ProLung submitted an application for marketing approval under Section 510(k) from the United States Food and Drug Administration, or FDA. In February 2015, we received a letter from the FDA identifying a number of issues, questions, and concerns in our application, including the risk classification of the test, the study design and study analysis along with what we consider other less important questions. In subsequent meetings with the FDA, ProLung succeeded in reducing the number of concerns and was asked to complete an additional study. We must complete the requested clinical research and resubmit the application with the results of the requested study and resolve or negotiate the removal of the remaining issues previously identified by the FDA as well as address possible issues to be identified in the future. Unless and until we obtain FDA approval, we may not market or sell our ProLung Test in the United States.

From inception to date, we have generated limited revenues. During the year ended December 31, 2014, we commenced selling the ProLung Test to customers in the European Union.

We plan to continue the development and deployment of medical devices and procedures specializing in the immediate, non-invasive evaluation of indeterminate masses in the lung seen in CT and radiography. We anticipate the need to fund expansion and market growth by raising capital over the next two years. The amount of capital needed could change based on the opportunities available to us and the ability to expand our markets.

We are an “emerging growth company” and a “smaller reporting company” under the federal securities laws and will be subject to reduced public company reporting requirements.

Results of Operations

The following discussion is included to describe our consolidated financial position and results of operations. The condensed consolidated financial statements and notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Three Months Ended September 30, 2017 compared to the Three Months Ended September 30, 2016

Revenues and Cost of Revenue. During the three months ended September 30, 2017 and September 30, 2016, we had no revenues and no cost of revenues.

Operating Expenses. Total operating expense for the three months ended September 30, 2017 was $1,341,909, compared to the total operating expenses for the three months ended September 30, 2016, of $601,981, representing an increase of $739,928. Operating expenses have been classified by management as either research and development expense or selling, general and administrative expense based on an assignment of certain expenses directly to these classifications or based on management’s allocation of certain expenses between these classifications. The overall increase in operating expense is primarily due to the Company having additional capital which has enabled the Company: 1) to access consultants for medical research, fundraising, business development and administrative and; 2) in anticipation of growing the operations the Company has hired additional personnel. This has increased payroll costs. A further discussion as to the increases in research and development expense and selling and general and administrative expense are more fully discussed below.

	Research and Development Expense. Research and development expense for the three months ended September 30, 2017 was $274,407, compared to research and development expense of $241,809 for the three months ended September 30, 2016; representing an increase of $32,598. This increase was partially due to an increase in payroll costs associated with the hiring of our new chief scientific officer, Dr. Rex Yung. Dr. Yung was hired in August to use his significant knowledge and experience to refine our ProLung Test and work towards getting FDA approval. We also had an increase in travel and professional fee costs related to our ongoing clinical trials. We would expect these costs to continue to increase as our clinical trials continue. This will require additional travel costs and the need for additional consultants to assist us in completing our final application with the FDA. These increases in research and development costs compared to the quarter ended September 30, 2016 were offset by a one-time stock compensation expense classified as research and development during the three months ended September 30, 2016. During 2017, we have not issued any stock based compensation that would be classified as research and development. However, there is no guarantee that we will not issue such items in the future.

	Selling, General and Administrative Expense. Selling, general and administrative for the three months ended September 30, 2017 was $1,067,502 compared to selling, general and administrative of $360,172 for the three months ended September 30, 2016; representing an increase of $707,330. This significant increase was due to the following events:

●

We had an increase in our payroll expense in the administrative area. In anticipation of our common stock listed on a stock exchange, we hired a CFO, controller, Director of Marketing and various administrative personnel. We made it a priority to enhance our accounting, investor relations and marketing personnel as these individuals play a critical role in our maintaining compliance.

	●	In anticipation of potentially having our common stock listed on a stock exchange, we have incurred significant travel, legal, professional and consulting expense. These costs relate to regulatory requirements, investor relations, brand awareness and indirect costs to obtain financing. Due to our filing a Registration Statement on Form S-1 during the current quarter, our costs for this quarter compared to last year have increased. We would expect these costs to be higher than the previous quarters in light of the significant legal, accounting and other expenses typically associated with a registered public offering. If such offering closes, we would expect higher legal, professional and consulting expense than experienced in years prior to 2017, but not at the same level as associated with the prospective offering.

	●	We had an increase in our expenses related to our Board of Directors. On August 24, 2017, the Board’s Compensation Committee approved the issuance of 52,500 options to our directors at exercise prices ranging from $8.00 to $10.00 per option. One half of the options (26,250) vested immediately with the remaining half (26,250) vesting quarterly through August 24, 2018. We recognized approximately $218,000 stock based compensation expense during the quarter and will recognize the remaining $96,000 through August 2018. We also paid director fees of $93,500 in cash during the quarter. Provided we become a fully trading Company, we will continue to pay these cash amounts every quarter. We incurred none of these costs during the quarter ended September 30, 2016.

	●	We incurred a non-cash stock based compensation expense of approximately $40,000 related to performance based options granted to our CEO during the quarter. On August 9, 2017, the Compensation Committee of the Board of Directors granted performance based stock options at an exercise price of $8.00 per option. The performance criteria are tied to FDA approval. Solely for accounting purposes, we have estimated that the conditions for vesting will be met between July and December 2018, which would cause 75,000 shares to vest. We valued these 75,000 options as of August 9, 2017 using the Black-Scholes Pricing Model resulting in a value of $472,000 which will be amortized over the estimated service period which is August 2017 through December 31, 2018. We had no similar expense during the quarter ended September 30, 2016.

Other income/(expense). Other income (expense) amounted to net expense of $24,211 for the three months ended September 30, 2017, as compared to net expense of $65,526 for the three months ended September 30, 2016. Other expense consists of interest expense. The decrease in interest expense during the three months ended September 30, 2017 compared to the prior year relates to convertible debentures being converted from October 2016 to August 2017. Otherwise, current interest expense represents interest accrued on the remaining convertible notes which are not due until 2020.

Nine months Ended September 30, 2017 compared to the Nine Months Ended September 30, 2016

Revenues and Cost of Revenue. During the nine months ended September 30, 2017 and September 30, 2016, we had no revenues. For the nine months ended September 30, 2017, there was no cost of revenues. For the nine months ended September 30, 2016, packaging valued at $10,193 was written off due to our new branding efforts and is reported as cost of revenues in the accompanying statement of operations.

Operating Expenses. Total operating expense for the nine months ended September 30, 2017 was $3,507,874, compared to total operating expenses for the nine months ended September 30, 2016, of $1,871,683, representing an increase of $1,636,191. Operating expenses have been classified by management as either research and development expense or selling, general and administrative expense based on an assignment of certain expenses directly to these classifications or based on management’s allocation of certain expenses between these classifications. The overall increase in operating expense is primarily due to the Company having additional capital which has enabled the Company: 1) to access consultants for medical research, fundraising, business development and administrative and; 2) in anticipation of growing the operations, the Company has hired additional personnel. This increases payroll costs. A further discussion as to the increases in research and development expense and selling and general and administrative expense are more fully discussed below.

Research and Development Expense. Research and development expense for the nine months ended September 30, 2017 was $1,034,934, compared to research and development expense of $806,052 for the nine months ended September 30, 2016; representing an increase of $228,882. This increase was due to the following events;

●

Increased payroll costs associated with reassigning certain staff to research and development as well as the hiring of new employees including our new Chief Scientific Officer. Due to the increase in clinical trials, further development of our ProLung Test and furthering our planned FDA application we needed to increase both the number and the quality of our research team. During the nine months ended September 30, 2016, we did not have the funds to fully accomplish this.

	●	Increase in travel, clinical and professional fees costs related to our ongoing clinical trials and focus on FDA approval. As of September 30, 2016, due to anticipated from a private offering, we expected these costs to increase during 2017. With increased clinical trials, we incur additional travel and clinical professional fees. With a greater focus on the FDA approval, we have engaged and will continue to engage certain professionals that will assist us in our efforts to get our FDA application completed, filed and approved.

	●	These increases in research and development costs compared to the nine months ended September 30, 2016 were offset by a one-time stock compensation expense classified as research and development during the three months ended September 30, 2016. During 2017, we have not issued any stock based compensation that would be classified as research and development. However, there is no guarantee that we will not issue such items in the future.

Selling, General and Administrative Expense. Selling, general and administrative expense for the nine months ended September 30, 2017 was $2,472,250, compared to selling, general and administrative expense of $1,065,631 for the nine months ended September 30, 2016; representing an increase of $1,406,619. This significant increase was due to the following events:

	●	In anticipation of potentially having our common stock listed on a stock exchange, as well as our fund-raising activities during the first half of 2017, we have incurred significant travel, legal, professional and consulting expense. These costs relate to regulatory requirements, investor relations, brand awareness and indirect costs to obtain financing. We also incurred non-cash stock based compensation to consultants. We would expect these costs to be higher than the previous periods in light of the significant legal, accounting and other expenses typically associated with a registered public offering. If such offering closes, we would expect higher legal, professional and consulting expense than experienced in years prior to 2017, but not at the same level as associated with the nine months ended September 30, 2017.

	●	We had an increase in our payroll expense in the administrative area. In anticipation of potentially having our common stock listed on a stock exchange, we hired a CFO, controller, Director of Marketing and various administrative personnel. We made it a priority to enhance our accounting, investor relations and marketing personnel, as these individuals play a critical role in our maintaining compliance.

	●	We had an increase in our expenses related to our Board of Directors. On August 24, 2017, the Board’s Compensation Committee approved the issuance of 52,500 options to the directors of the Company at exercise prices ranging from $8.00 to $10.00 per option. One half of the options (26,250) vested immediately with the remaining half (26,250) vesting quarterly through August 24, 2018. We recognized approximately $218,000 in stock based compensation expense during the nine months ended September 30, 2017 and will recognize the remaining $96,000 through August 2018. We also paid director fees of $93,500 year to date. Provided our common stock is listing on a stock exchange, we will continue to pay approximately $93,500 to our directors as a group every quarter. We incurred none of these costs during the nine months ended September 30, 2016.

	●	We incurred a non-cash stock based compensation expense of approximately $40,000 related to performance based options granted to our CEO. On August 9, 2017, the Compensation Committee of the Board of Directors granted performance based stock options at an exercise price of $8.00 per option. The performance criteria is tied to FDA approval. Solely for accounting purposes, we have estimated that the conditions for vesting will be met between July and December 2018 , which would cause 75,000 shares to vest. We valued these 75,000 options as of August 9, 2017 using the Black-Scholes Pricing Model resulting in a value of approximately $472,000 which will be amortized over the estimated service period which is August 2017 through December 31, 2018. We had no similar expense during the nine months ended September 30, 2016.

Other income/(expense). Other income (expense) amounted to net expense of $97,957 for the nine months ended September 30, 2017, as compared to net expense of $204,282 for the nine months ended September 30, 2016. Other expense consists of interest expense. The decrease in interest expense during the nine months ended September 30, 2017 principally relates to the conversion of most of the convertible debentures, which were previously accruing interest.

Liquidity and Capital Resources

The following is a summary of our key liquidity measures at September 30, 2017 and December 31, 2016:

	September 30, 2017			December 31, 2016

Cash	$	1,783,449		$	28,922

Current assets	$	2,135,390		$	37,753
Current liabilities		(259,634	)		(760,175	)

Working capital (deficit)	$	1,875,756		$	(722,422	)

If we obtain FDA clearance to market the ProLung Test in the U.S., we expect that our need for capital will expand. We estimate the cash outflows necessary for the marketing launch, including the ramp up to deploy sales and distribution, will be approximately $8,000,000 over an 18 to 24-month period. If we are able to close our proposed registered public offering, proceeds from that offering would potentially provide part of the $8,000,000 we anticipate would be needed. We expect that in order to raise such capital we will be required to issue equity securities, debt securities and rights to acquire equity securities. We have no existing commitment to provide capital. Given our early stage of development, we may be unable to raise sufficient capital when needed and, in any case, may require us to issues shares, rights to acquire shares, or debt on onerous terms in order to be able to raise capital.

Our future capital requirements and adequacy of available funds will depend on many factors including:

	●	our ability to obtain regulatory approval in the United States;

	●	our ability to successfully commercialize our ProLung Test, ProLung Scanner and related products and the market acceptance of these products;

	●	the pace of our orders, if any, and the pricing and payment terms of those orders;

	●	our ability to establish and maintain collaborative arrangements with corporate partners for the development and commercialization of certain product opportunities;

	●	whether our common stock is listed on a market and, if so, the price of and trading volume associated with our common stock;

	●	the cost of manufacturing and production scale-up;

	●	our financial results;

	●	the cost and availability of capital generally; and

	●	the occurrence of unexpected adverse expenses or events.

Long-Term Debt

Since our inception, the principal source of our financing has come from the issuance of equity securities and from debt financing. As of September 30, 2017, our outstanding debt financing includes the following borrowing arrangement.

Convertible Notes Payable

Cash provided by (used in) operating, investing and financing activities for the nine months ended September 30, 2017 and 2016 is as follows:

	September 30,
	2017			2016

Operating activities	$	(3,426,791	)	$	(1,454,514	)
Investing activities		(19,448	)		-
Financing activities		5,200,766			1,044,224

Net increase (decrease) in cash	$	1,754,527		$	(410,290	)

Operating Activities

For the nine months ended September 30, 2017 and 2016, the differences between our net loss and net cash used in operating activities were due to net non-cash charges primarily related to stock-based compensation and depreciation. Due to increased capital we were able to expand our operations and simultaneously settle various previous operating obligations, which resulted in more cash being used in operating activities during 2017 as compared to 2016.

Investing Activities

During the nine months ended September 30, 2017, our cash flows used in investing activities were primarily for the purchase of office equipment, net of a small amount proceeds from the sale of equipment. During the nine months ended September 30, 2016, the Company had no activities classified as investing activities.

Financing Activities

During the nine months ended September 30, 2017 our cash inflows from financing activities were related to proceeds received from our private placements of common shares and warrants to acquire common shares which concluded in the 2^nd quarter. Our outflows of cash related to financing activities revolved around cash settlement of remaining debenture holders, third party loans and related party loans. We also had cash outflows for direct and deferred offering costs related to the above mentioned private placement and costs incurred to date on our potential public offering.

During the nine months ended September 30, 2016, cash inflows from financing activities related to initial proceeds from our private placement as well as loans from related parties. The outflows consist of payments on related party debt.

Critical Accounting Policies and Estimates

Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Inventory – Inventory is valued at the lower of cost or market value, with cost determined based on the first-in-first-out method. Management evaluates inventory for obsolescence based on expectations about future demand and marketability of products, and if necessary, reduces inventory to the lower of cost or market through the use of on inventory valuation account for obsolescence. The estimated cost of inventory not expected to be converted to cash within one year is reflected as “Inventory, noncurrent” in the condensed consolidated balance sheets.

Long-lived Assets – Long-lived assets, including property and equipment, and intangible assets are tested for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. When such events occur, we compare the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset or asset group to the carrying amount of the long-lived asset or asset group. If this comparison indicates that there is an impairment, the amount of the impairment is calculated based on fair value.

Stock-based Compensation – The Company measures the cost of employee and consulting services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The awards issued are valued using a fair value-based measurement method. The resulting cost is recognized over the period during which an employee or consultant is required to provide services in exchange for the award, usually the vesting period.

Emerging Growth Company – We are an “emerging growth company” under the federal securities laws and will be subject to reduced public company reporting requirements. In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

Off Balance Sheet Arrangements

The Company has not had any off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company and, as a result, are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of September 30, 2017. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Based on that evaluation, our chief executive officer and chief financial officer concluded as of September 30, 2017 that our disclosure controls and procedures are designed at a reasonable assurance level and were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure as a result the following material weakness in our internal controls and procedures existed:

The Company did not maintain effective entity-level internal controls as defined by the framework issued by COSO. Specifically, the Company did not effectively segregate certain accounting duties due to the small size of the Company’s accounting staff, and did not maintain a sufficient number of adequately-trained personnel necessary to anticipate and identify risks critical to financial reporting.

In order to mitigate these material weaknesses to the fullest extent possible, all financial reports are reviewed by the Chief Executive Officer. We have recently hired a Chief Financial Officer that is familiar with SEC Regulatory requirements and have also recently hired a controller. In addition, we engage a third-party accounting firm to provide additional expertise in accounting for non-routine or complex transactions.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting that occurred in the quarter ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There have occurred no events requiring disclosure under this item.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and, as a result, are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The offer and sale of such warrants to purchase common stock and the underlying shares, is being effected in reliance upon the exemptions for sales of securities not involving a public offering, as set forth in Section 4(a)(2) of the Securities Act, based upon the following: (a) the consultant has confirmed to us that the consultant was an “accredited investor,” as defined in Rule 501 promulgated under the Securities Act and had such background, education and experience in financial and business matters as to be able to evaluate the merits and risks of an investment in the securities; (b) there was no public offering or general solicitation with respect to such offering; (c) the consultant was provided with certain disclosure materials and all other information requested with respect to our company; (d) the consultant acknowledged that all securities being purchased were “restricted securities” for purposes of the Securities Act, and agreed to transfer such securities only in a transaction registered under the Securities Act or exempt from registration under the Securities Act; and (e) a legend was placed on the certificates representing each such security stating that it was restricted and could only be transferred if subsequently registered under the Securities Act or transferred in a transaction exempt from registration under the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

See the Exhibit index below.

Exhibit Number		Description

3.1		Third Amended and Restated Certificate of Incorporation^{(1) (2)}

3.2		Amended and Restated By-Laws⁽²⁾

31.1		Certification Pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as Amended*

31.2		Certification Pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as Amended*

32.1		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

32.2		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101 INS		XBRL Instance Document*

101 SCH		XBRL Schema Document*

101 CAL		XBRL Calculation Linkbase Document*

101 LAB		XBRL Labels Linkbase Document*

101 PRE		XBRL Presentation Linkbase Document*

101 DEF		XBRL Definition Linkbase Document*

* Filed herewith

	(1)	Incorporated by reference to the Current Report on Form 8-K filed on October 13, 2017 .
	(2)	Incorporated by reference to the Current Report on Form 8-K filed on July 19, 2017 .

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ProLung, Inc.

November 14, 2017	By:	/s/ Steven C. Eror
Date		Steven C. Eror,
		Chief Executive Officer and President (Principal Executive Officer)

November 14, 2017	By:	/s/ Mark V. Anderson
Date		Mark V. Anderson
		Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven C. Eror, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of ProLung, Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

	(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 14, 2017

/s/ Steven C. Eror

Steven C. Eror, Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark V. Anderson, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of ProLung, Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

	(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:

November 14, 2017

/s/ Mark V. Anderson

Mark V. Anderson, Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ProLung, Inc. (the “Company”) for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission (the “Report”), I, Steven C. Eror, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:

November 14, 2017

/s/ Steven C. Eror

Steven C. Eror

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ProLung, Inc. (the “Company”) for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission (the “Report”), I, Mark V. Anderson, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:

November 14, 2017

/s/ Mark V. Anderson

Mark V. Anderson

Chief Financial Officer

(Principal Financial Officer)

EX-101.INS 6 prl-20170930.xml XBRL INSTANCE FILE 0001541884 2017-01-01 2017-09-30 0001541884 2017-09-30 0001541884 2016-12-31 0001541884 2017-07-01 2017-09-30 0001541884 2016-07-01 2016-09-30 0001541884 2016-01-01 2016-09-30 0001541884 2015-12-31 0001541884 2016-09-30 0001541884 us-gaap:ConvertibleDebtMember 2017-01-01 2017-09-30 0001541884 PRL:PlacementAgentAgreementMember 2017-09-30 0001541884 PRL:PlacementAgentAgreementMember us-gaap:MaximumMember 2017-09-30 0001541884 PRL:PlacementAgentAgreementMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001541884 PRL:ConvertibleNotesMember 2015-12-31 0001541884 PRL:ConvertibleNotesMember us-gaap:CommonStockMember 2015-12-31 0001541884 PRL:NotePayableToARelativeOfAnExecutiveOfficerMember 2017-09-30 0001541884 PRL:NotePayableToARelativeOfAnExecutiveOfficerMember 2017-01-01 2017-09-30 0001541884 PRL:OtherNotesPayableMember 2017-01-01 2017-09-30 0001541884 PRL:RelatedPartyNotePayableMember 2017-09-30 0001541884 PRL:RelatedPartyNotePayableMember 2017-01-01 2017-09-30 0001541884 us-gaap:PrivatePlacementMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001541884 us-gaap:PrivatePlacementMember us-gaap:MinimumMember 2017-09-30 0001541884 us-gaap:PrivatePlacementMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001541884 us-gaap:PrivatePlacementMember us-gaap:MaximumMember 2017-09-30 0001541884 us-gaap:PrivatePlacementMember 2017-09-30 0001541884 PRL:TwoSeparatePlacementAgentsMember 2017-01-01 2017-09-30 0001541884 PRL:TwoSeparatePlacementAgentsMember 2017-09-30 0001541884 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001541884 us-gaap:RestrictedStockMember 2016-12-31 0001541884 us-gaap:RestrictedStockMember 2017-09-30 0001541884 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001541884 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001541884 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001541884 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001541884 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001541884 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0001541884 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001541884 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0001541884 PRL:WarrantsMember 2017-01-01 2017-09-30 0001541884 PRL:WarrantsMember 2016-01-01 2016-09-30 0001541884 PRL:WarrantsMember 2017-07-01 2017-09-30 0001541884 PRL:WarrantsMember 2016-07-01 2016-09-30 0001541884 PRL:WarrantsMember 2016-12-31 0001541884 PRL:WarrantsMember 2017-09-30 0001541884 PRL:ConsultingAgreementMember PRL:DrRobinSmithMember 2017-02-01 2017-02-28 0001541884 PRL:LeaseAgreementMember 2017-01-01 2017-09-30 0001541884 PRL:LicenseAgreementMember 2017-09-30 0001541884 PRL:LicenseAgreementMember 2016-12-31 0001541884 us-gaap:ConvertibleDebtMember 2017-09-30 0001541884 PRL:ConvertibleNotePayableMember 2017-09-30 0001541884 PRL:ConvertibleNotePayableMember 2017-01-01 2017-09-30 0001541884 PRL:SecuredNotePayableMember 2017-09-30 0001541884 PRL:SecuredNotePayableMember 2017-01-01 2017-09-30 0001541884 PRL:RelatedPartyNotePayableMember 2017-09-30 0001541884 PRL:RelatedPartyNotePayableMember 2017-01-01 2017-09-30 0001541884 PRL:UnsecuredNotePayableMember 2017-09-30 0001541884 PRL:UnsecuredNotePayableMember 2017-01-01 2017-09-30 0001541884 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001541884 PRL:NonVestedSharesMember 2017-07-01 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember 2017-07-01 2017-09-30 0001541884 PRL:ConvertibleNoteMember 2017-07-01 2017-09-30 0001541884 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001541884 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001541884 PRL:NonVestedSharesMember 2017-01-01 2017-09-30 0001541884 PRL:NonVestedSharesMember 2016-01-01 2016-09-30 0001541884 us-gaap:ConvertibleDebtMember 2017-01-01 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember 2016-01-01 2016-09-30 0001541884 PRL:ConvertibleNoteMember 2017-01-01 2017-09-30 0001541884 PRL:ConvertibleNoteMember 2016-01-01 2016-09-30 0001541884 us-gaap:WarrantMember 2016-07-01 2016-09-30 0001541884 PRL:NonVestedSharesMember 2016-07-01 2016-09-30 0001541884 us-gaap:ConvertibleDebtMember 2016-07-01 2016-09-30 0001541884 PRL:ConvertibleNoteMember 2016-07-01 2016-09-30 0001541884 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001541884 us-gaap:CommonStockMember 2016-12-31 0001541884 us-gaap:CommonStockMember 2017-09-30 0001541884 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001541884 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001541884 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001541884 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001541884 us-gaap:RetainedEarningsMember 2016-12-31 0001541884 us-gaap:RetainedEarningsMember 2017-09-30 0001541884 2017-11-10 0001541884 PRL:BoardOptionGrantsMember 2017-01-01 2017-09-30 0001541884 PRL:CEOStockoptionIncentiveMember 2017-01-01 2017-09-30 0001541884 us-gaap:StockOptionMember 2017-07-01 2017-09-30 0001541884 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001541884 us-gaap:StockOptionMember 2016-07-01 2016-09-30 0001541884 us-gaap:StockOptionMember 2016-01-01 2016-09-30 0001541884 PRL:RelatedPartyNotePayableMember 2016-09-30 0001541884 PRL:RelatedPartyNotePayableMember 2016-01-01 2016-09-30 0001541884 us-gaap:MaximumMember 2017-07-30 0001541884 us-gaap:MinimumMember 2017-07-30 0001541884 PRL:ConsultantMember 2017-09-30 0001541884 us-gaap:PrivatePlacementMember us-gaap:MaximumMember PRL:BoardOfDirectorsMember 2017-02-01 2017-02-28 0001541884 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001541884 us-gaap:ConvertibleDebtMember us-gaap:ExecutiveOfficerMember 2017-01-01 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember us-gaap:ExecutiveOfficerMember 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember PRL:RelatedPartyMember 2017-01-01 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember PRL:RelatedPartyMember 2017-09-30 0001541884 PRL:TwoConsultantsMember 2017-01-01 2017-09-30 0001541884 PRL:DirectorsOfficersAndConsultantsMember 2017-01-01 2017-09-30 0001541884 PRL:DirectorsOfficersAndConsultantsMember 2016-01-01 2016-09-30 0001541884 PRL:StockIncentivePlanMember 2017-04-30 0001541884 PRL:StockIncentivePlanMember 2017-04-01 2017-04-30 0001541884 PRL:StockOptionIncentivePlanMember PRL:JanuaryOneTwoThousandAndTwentySevenMember 2017-04-30 0001541884 PRL:DirectorsMember 2017-04-01 2017-04-30 0001541884 PRL:DirectorsMember us-gaap:MinimumMember 2017-04-01 2017-04-30 0001541884 PRL:DirectorsMember us-gaap:MaximumMember 2017-04-01 2017-04-30 0001541884 PRL:DirectorsMember PRL:ThroughAugustTwoThousandAndEighteenMember 2017-04-01 2017-04-30 0001541884 PRL:ThroughAugustTwoThousandAndEighteenMember 2017-09-30 0001541884 PRL:EmploymentAgreementMember 2017-03-28 2017-03-29 0001541884 PRL:EmploymentAgreementMember PRL:USFoodAndDrugAdministrationMember PRL:OnOrBeforeJanuaryOneTwoThousandAndEighteenMember 2017-03-28 2017-03-29 0001541884 PRL:EmploymentAgreementMember PRL:USFoodAndDrugAdministrationMember PRL:OnOrBeforeJulyOneTwoThousandAndEighteenMember 2017-03-28 2017-03-29 0001541884 PRL:EmploymentAgreementMember PRL:USFoodAndDrugAdministrationMember PRL:OnOrBeforeJanuaryOneTwoThousandAndNineteenMember 2017-03-28 2017-03-29 0001541884 PRL:EmploymentAgreementMember PRL:USFoodAndDrugAdministrationMember PRL:OnOrBeforeJanuaryOneTwoThousandAndTwentyMember 2017-03-28 2017-03-29 0001541884 PRL:BoardOfDirectorsMember 2017-08-08 2017-08-09 0001541884 PRL:ThroughDecemberThirtyOneTwoThousandAndEighteenMember 2017-08-08 2017-08-09 0001541884 PRL:StockOptionIncentivePlanMember 2017-01-01 2017-09-30 0001541884 PRL:StockOptionIncentivePlanMember us-gaap:ChiefExecutiveOfficerMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001541884 PRL:BoardOptionGrantsMember 2017-09-30 0001541884 PRL:CEOStockoptionIncentiveMember 2017-09-30 0001541884 us-gaap:SubsequentEventMember PRL:EmployeesMember 2017-11-09 2017-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PROLUNG INC 0001541884 10-Q 2017-09-30 false --12-31 Smaller Reporting Company Q3 2017

1783449

28922

20981

8831

2135390

37753

314465

291559

2693073

577967

194957

358477

64677

264698

105000

32000

259634

760175

1206931

2653370

1466565

3413545

3862

3001

20914110

13247054

-19691464

-16085633

1226508

-2835578

3001

3862

13247054

20914110

-16085633

-19691464

2693073

577967

330960

0.001

10000000

0.001

120000000

500000

900000

3861598

3000815

67258

40000

3861598

3000815

10193

-10193

1034934

274407

241809

806052

2472250

1067502

360172

1065631

3507874

1341909

601981

1871683

-3507874

-1341909

-601981

-1881876

97957

24211

65526

204282

-97957

-24211

-65526

-204282

-1.02

-0.35

-0.23

-0.75

3522810

3849791

2870596

2793738

-3605831

-1366120

-667507

-2086158

-3605831

-690

24195

24889

385013

261153

110769

332241

79915

227392

261153

30854

385013

104849

70360

67945

35446

33912

-10193

22906

162379

12150

-26964

-163520

230306

-32282

169430

-3426791

-1454514

19842

394

-19448

995412

6531567

882224

164000

32000

105000

55000

185000

50000

55000

5200766

1044224

1754527

-410290

1783449

28922

451526

41236

169623

48744

1255789 785167 60000

66846

69264

11222

31185

236397

191110

314465

291559

-314465

291559

234405

39071

50000

17873

46804

12420

25700

1185

5000

599

717950

1093050

100000

55000

162739 60000

1206931

89389

55000

160000

241500

8334

5000

8334

5000

6.48

6.00

5.20

12.00

5.20

12.00

330425

330433

8334

5000

P36M

0.08

0.0800

0.1500

0.08

0.1000

28.00

12.00

1.50

1206931 2653370

1257050

1206931 1206931

189389

32000

1206931

2790370

40000000

120000000

41667

437500

682669

500000

5250000

8200000

82380

41667

826146

882224

6531567

67217

162739

5000

150994

249834

5.20

6250

2496

53500

53494

29651

109

127500

52500

150000

112500

75000

37500

75000

372500

150000

204250

-109

26250

4.00

2.34

5.97

6.32

6.08

4.00

0.0184

0.0133

0.0184

1.22

1.24

1.07

1.24

P4Y6M0D

P4Y2M12D

P5Y1M13D

P5Y9M

0.00

7.28

127500

8.14

8.00

10.00

8.00

P9Y10M25D

90000

P9M

4140

35997

34917

17873

153681

73761

113000

348000

during 2017

due November 6, 2020

during 2017

FRES

1205623

201155

1205623

177901

1359

275509

201155

205212

177901

1359

275509

205212

127500

52500

0.03

Note 2 – Inventory   Inventory consists of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 107%">Raw materials</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">66,846</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">69,264</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Work in progress</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">11,222</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">31,185</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Finished goods</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">236,397</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">191,110</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Total inventory</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">314,465</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">291,559</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Less carrying value of inventory not deemed to be a current asset</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(314,465</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(291,559</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Inventory, included in current assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

Note 1 – Organization and Summary of Significant Accounting Policies   Organization   ProLung, Inc. (formerly Fresh Medical Laboratories, Inc.) (the “Company”) is a Delaware corporation that was incorporated on November 22, 2004. The Company’s headquarters are located in Salt Lake City, Utah. The Company’s business is the development, marketing, and sale of precision predictive analytical medical devices specializing in lung cancer. The Company’s principal activities are primarily developing markets for its products, securing strategic alliances and obtaining financing.   Principles of Consolidation   During the year ended December 31, 2012, the Company formed a wholly-owned subsidiary, Hilltop Acquisition Corporation, Inc., which has had no activity since its inception and is included in the accompanying condensed consolidated financial statements from the date of its formation.   Reverse Stock Split   On October 10, 2017, the Company’s Board of Directors approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effectuate a 1-for-8 reclassification, or reverse stock split, of the Company’s common stock, to be effective as of October 25, 2017. All share, option, warrant, per share, per option and per warrant amounts in the condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to the reverse stock split.   Basis of Presentation   The accompanying condensed consolidated financial statements have been prepared by management in accordance with rules and regulations promulgated by the U.S. Securities and Exchange Commission and therefore certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments necessary for them to be presented fairly, with those adjustments consisting only of normal recurring adjustments. These interim financial statements should be read in conjunction with the Company’s consolidated financial statements as of, and for the year ended, December 31, 2016 included in the Company’s Amendment No. 3 to the Annual Report on Form 10-K for the year ended December 31, 2016. The results of operations for the three and nine months ended September 30, 2017 may not be indicative of the results to be expected for the year ending December 31, 2017.   The Company has incurred losses since inception while pursuing the development of its primary predictive analytical medical device, and approval from the U.S. Food and Drug Administration (“FDA”) to market the device, while also developing markets outside the United States. The Company incurred net losses of $3.6 million and $2.1 million for the nine months ended September 30, 2017 and 2016, respectively. Cash used in operating activities was $3.4 million and $1.5 million for the nine months ended September 30, 2017 and 2016, respectively. Historically, operations have been funded primarily through the sale of equity or debt securities. Should management continue to fund operations at similar levels, additional equity or debt securities would need to be sold, or other financing arrangements made.   The Company has the ability to maintain current levels of spending, or reduce expenditures significantly if funding is not available. Additionally, should FDA approval be obtained, the Company could execute on an aggressive marketing plan that would require significant additional funding; however, this plan would not begin until funding is in place.   Basic and Diluted Loss Per Share   The Company computes basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. The Company computes diluted loss per share by dividing net loss by the sum of the weighted-average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of diluted loss per share does not assume exercise or conversion of securities that would have an anti-dilutive effect. As of September 30, 2017, and 2016, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Three and Nine Months Ended</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Warrants to purchase shares</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">1,205,623</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">177,901</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Stock options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">127,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,359</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Convertible debentures</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">275,509</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">201,155</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">205,212</td> <td style="line-height: 107%"> </td></tr> </table>   Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was amended with ASU No. 2015-14, ASU No. 2016-08, ASU No. 2016-10, ASU No. 2016-12 and ASU No. 2016-20. These new standards supersede all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The Company is evaluating the guidance but does not at this time expect it to have a material impact on the Company’s revenue recognition. However, the Company does expect to have significant changes to the footnote disclosures related to revenue recognition as a result of implementing these new standards. As the Company is an emerging growth company, this standard will be implemented effective January 1, 2019.   In February 2016, the FASB issued ASU No. 2016-02: Leases ASU 2016-02 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. ASU 2016-02 will be effective for the Company’s fiscal year beginning January 1, 2019, on a modified retrospective basis and earlier adoption is permitted. Management is currently evaluating the impact of the pending adoption of ASU 2016-02 on the Company’s consolidated financial statements.   In November 2016, the FASB issued an ASU amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt this ASU on January 1, 2018 and does not expect any accounting significance upon adoption.   In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. This Standard was issued to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt this ASU on January 1, 2018, since this standard is to be applied prospectively there will be no effect on prior financial statements and the Company does not currently have plans where this standard would be applicable.   In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II). Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down round features. Part II simply replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within Accounting Standards Codification (ASC) Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. This ASU is effective for public companies for the annual reporting periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of the standard may have on its consolidated financial statements and does not anticipate early adopting.   ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities was issued in August 2017. The amendments under ASU 2017-12 refine and expand hedge accounting requirements for both financial (e.g., interest rate) and commodity risks. Its provisions create more transparency around how economic results are presented, both on the face of the financial statements and in the footnotes. It also makes certain targeted improvements to simplify the application of hedge accounting guidance. ASU 2017-12 becomes effective for the Company in the first quarter of 2019. The Company is currently assessing the impact the adoption of this ASU will have on the consolidated financial statements.

Note 3 – Accrued Liabilities   Accrued liabilities consisted of the following at September 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 107%">Accrued interest</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">234,405</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accrued royalties</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">17,873</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">17,873</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accrued payroll and payroll taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">46,804</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">12,420</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total accrued liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">64,677</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">264,698</td> <td style="line-height: 107%"> </td></tr> </table>

Note 4 –Short and Long-term Debt   Short and Long-term debt is summarized as follows   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Convertible debentures; unsecured; interest at 8.00% per annum; settled during 2017</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">1,257,050</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes payable; unsecured; interest at 8.00% per annum; due November 6, 2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Note payable secured by all the assets of the Company; interest at 15.00% per annum; settled during 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">189,389</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Related-party note payable; interest at 8%; settled during 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">105,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Unsecured note payable; interest at 10.00% per annum; settled during 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">32,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total long-term debt</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,790,370</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less:  current portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">137,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Long-term debt, net of current portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,653,370</td> <td style="line-height: 107%"> </td></tr> </table>   Convertible Debentures   During the nine months ended September 30, 2017 convertible debentures were converted or repaid as follows: The Company repaid $164,000 in principal along with $25,700 in related accrued interest. The remaining convertible debenture holders elected to convert $1,093,050 in principal along with $162,739 in related interest into 241,500 shares of common stock at a rate of $5.20 per share.   As further described in Note 5 to these unaudited condensed consolidated financial statements, the Company entered into placement agent agreements that provide for compensation to the respective placement agent in connection with an offering of common stock. Additionally, the placement agent agreements provide for potential compensation to the placement agent in connection with the future conversion of the convertible debentures into shares of common stock of the Company. Upon the conversion of the convertible debentures, the Company was required to issue the placement agent warrants to acquire shares of the Company’s common stock at an exercise price of $5.20 per share. The placement agent will be issued a warrant to purchase one share of common stock for each $6.48 of the principal amount of the convertible debentures converted into common stock, with the maximum number of warrants issuable under the Placement Agreement limited to 330,433 shares of the Company’s common stock. The term of the warrants is for a period of 36 months from the date of issuance. During the nine months ended September 30, 2017, 330,425 warrants were issued to then-current placement agent.   Convertible Notes Payable   In 2015, the Company issued two convertible promissory notes (the “convertible notes”) in the aggregate principal amount of $1,206,931 to two investment entities controlled by a single family. The convertible notes are unsecured and accrue interest at the rate of 8% per annum, with interest payable on the last day of each calendar quarter. The principal amount under the convertible notes is due on the five-year anniversary of the issue date. The convertible notes are convertible at any time prior to maturity at the option of the holders at a conversion rate of $6.00 per share. If the Company’s common stock commences trading and closes at a price of $28.00 per share for five consecutive trading days, the principal amount under the convertible notes automatically converts into common stock at the rate of $6.00 per share.   Note Payable to a Relative of an Executive Officer   During the nine months ended September 30, 2017, $89,389 of principal of a master note to an individual related to an executive officer of the Company was repaid along with interest of $39,071. In addition, the noteholder elected to convert the remaining $100,000 of principal for 8,334 shares of common stock as well as 8,334 warrants to purchase stock at a price of $12.00 per unit.   Other Notes Payable   During the nine months ended September 30, 2017, the Company repaid $32,000 of principal along with $1,185 of related accrued interest. These proceeds were received during the nine months ended September 30, 2016.   Related-Party Note payable   During the nine months ended September 30, 2017, $105,000 of principal of related-party notes was repaid along with interest and fees of $5,000. $55,000 of this principal and the related interest was settled in common stock and $50,000 was settled in cash. The related party elected to convert $60,000 of principal and interest into 5,000 shares, as well as 5,000 warrants to purchase stock, at a price of $12.00 per unit.   During the nine months ended September 30, 2016, the Company issued notes to a related-party for $185,000. Also during the nine months ended September 30, 2016, $55,000 of the related-party notes were paid back along with interest and fees of $599.

Note 5 – Common Stock   Increase in Authorized Shares   In July, 2017, following the receipt of board authorization and stockholder approval, the Company filed an Amended and Restated Certificate of Incorporation which, among other things, increased the authorized number of shares of common stock from 40,000,000 shares to 120,000,000. The increase in authorized shares has been reflected on the Company’s condensed consolidated balance sheet.   Public Offering of Common Stock of the Company   On August 4, 2017, the Company filed a Registration Statement on Form S-1 (as modified from time to time, the “Registration Statement”), to which it filed a pre-effective amendment on October 17, 2017. This Registration Statement relates to a potential public offering of the Company’s common stock. Such Registration Statement is subject to review before it becomes effective. There is no assurance that any shares will be offered and sold pursuant to such Registration Statement. During the nine months ended September 30, 2017, the Company has incurred cash offering costs totaling $330,960 which will be offset against the proceeds received, if such offering is completed. If the Company does not complete the offering, the deferred offering costs will be charged to expense.   Private Placement of Common Stock of the Company   The Company has been issuing equity under a private placement agreement. The Company offered a minimum of 41,667 units, comprised of one share of common stock and one warrant to purchase one share of common stock at $12.00, or a maximum of 437,500 units at a purchase price of $12.00 per unit, for a minimum offering amount of $500,000 and a maximum offering amount of $5,250,000, which maximum amount was increased to 682,669 units, and $8.2 million by the Board of Directors in February 2017. The units were offered to a limited number of prospective investors who qualify as “accredited investors.” The units were offered on a “best efforts, all-or-none” basis for the first 41,667 units subscribed for and on a “best efforts” basis thereafter.   The Company engaged two separate placement agents during different time periods in connection with the offering, which placement agents were entitled to a cash commission of ten percent of the issuance price of the common stock sold in the offering, and one share of common stock of the Company for each ten shares of the Company’s common stock sold in the offering. Pursuant to these agreements, the Company had incurred commission fees to the placement agents of $826,146 together with 68,268 shares of common stock as of September 30, 2017. For the nine months ended September 30, 2017, the Company received subscriptions for $6,531,567 and paid $664,452 in offering costs.   During the nine months ended September 30, 2016, 82,380 shares were subscribed, conditions for the minimum offering were met, and the Company received net proceeds of $882,224 from the offering.   As of September 30, 2017, the adjusted maximum offering amount of $8.2 million was subscribed for and the offering was closed.   Common Stock Issued for Conversion of Convertible Debentures and Notes Payable   During the nine months ended September 30, 2017, $1,093,050 of convertible debentures and $162,739 of accrued interest was converted at $5.20 per share into 241,500 shares of common stock. As partial settlement of a note payable to a relative of an executive officer, $100,000 was converted at $12.00 per share into 8,334 shares of common stock. Also, in partial settlement of a related party note, $55,000 of principal and $5,000 of interest was converted at $12.00 per share into 5,000 shares of common stock.   During the nine months ended September 30, 2016, certain convertible debenture holders exercised their right and converted $717,950 of principal and $67,217 of accrued interest into common stock. The Company issued 150,994 shares of common stock at $5.20 per share.   Common Stock Issued for Services   In addition, during the nine months ended September 30, 2016, the Company issued 2,496 shares of common stock with a total value of $29,651 to two consultants for services rendered.   The Company recognized stock-based compensation related to the shares issued to directors, officers and consultants for the nine months ended September 30, 2017 and 2016 of $53,500 and $332,241, respectively.   Periodically, the Company issues non-vested common stock to directors, officers and consultants as compensation for future services. During the nine months ended September 30, 2017 and 2016, the Company recognized $433 and $121,400 in stock compensation expense related to the amortization of this deferred compensation.   A summary of the status of the Company’s restricted common stock grants as of September 30, 2017 and changes during the nine months then ended, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Restricted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Common</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Stock</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Common</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Grants</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Stock Price</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%">Balance at December 31, 2016</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">109</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">4.00</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Awarded</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Vested</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(109</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.00</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Balance at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> </table>   As of September 30, 2017, there are no longer any restricted common stock grants.   Total stock-based compensation expense from all sources for the three and nine months ended September 30, 2017 and 2016, including stock-based compensation for the options and warrants discussed in Note 6 and 7, has been included in the unaudited condensed consolidated statements of operations as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Three Months Ended</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Nine Months Ended</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Research and development expense</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">79,915</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">227,392</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Selling, general and administrative expense</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">261,153</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">30,854</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">385,013</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">104,849</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total share-based compensation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">261,153</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">110,769</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">385,013</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">332,241</td> <td style="line-height: 107%"> </td></tr> </table>

Note 7 – Common Stock Warrants   The Company has issued warrants to purchase its common stock for payment of consulting services, in connection with the extension of a note payable, as incentives to investors, and for cash. The fair value of warrants issued for consulting services is recognized as consulting expense at the date the warrants become exercisable. The Company values non-vested warrants utilizing the Black Scholes Method and records compensation over the requisite service period which is usually the vesting period. The fair value of warrants was estimated using the Black-Scholes option pricing model. The fair value of the warrants that vested during the nine months ended September 30, 2017 was $6.32 per warrant. The weighted-average assumptions used for the warrants that vested during the nine months ended September 30, 2017 were risk-free interest rate of 1.84%, expected volatility of 122%, expected life of 4.5 years, and expected dividend yield of zero. The fair value of the warrants that vested during the year ended December 31, 2016 was $6.08 per warrant. The weighted-average assumptions used for the warrants that vested during the year ended December 31, 2016 were risk-free interest rate of 1.33%, expected volatility of 124%, expected life of 4.5 years, and expected dividend yield of zero. The Company recognized $70,360 and $67,945 as share-based compensation and additional paid-in capital related to the vesting of warrants for the nine months ended September 30, 2017 and 2016 respectively. The Company recognized $35,446 and $33,912 as share-based compensation related to the vesting of warrants for the three months ended September 30, 2017 and 2016, respectively.   In September 2017, the Company issued 1,250 warrants to a consultant for investor relation services rendered. The warrants have an exercise price of $12 per warrant, vest immediately and expire in September 2020. The fair value of these warrants was $2,926 or $2.34 per warrant and was immediately recognized as an expense. The fair value was computed using the Black Scholes method using the following assumptions.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; line-height: 107%">Expected life </td> <td style="width: 50%; text-align: right; line-height: 107%">1.52 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Exercise price</td> <td style="text-align: right; line-height: 107%">$12.00 </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected volatility</td> <td style="text-align: right; line-height: 107%">107%</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected dividends</td> <td style="text-align: right; line-height: 107%">None</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="text-align: right; line-height: 107%">1.33%</td></tr> </table>   A summary of warrant activity for the nine months ended September 30, 2017 is presented below:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Shares</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Value of</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Under</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Contractual</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Vested</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; line-height: 107%">Outstanding at December 31, 2016</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">430,938</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">7.04</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%"> 4.2 years </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">546,333</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">774,685</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">10.11</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> 2.2 years </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,205,623</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">9.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> 2.8 years </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1,230,829</td> <td style="line-height: 107%"> </td></tr> </table>   The intrinsic value at September 30, 2017 is calculated at $7.28 per share less the exercise price, based on the management’s latest estimate of the fair value of the shares of common stock, which is the latest price the Company issued shares of common stock for cash.

Note 8 – Commitments and Contingencies   Consulting Representation Agreement   In February 2017, the Company entered into a consulting agreement with Dr. Robin Smith, who is a director of the Company. Under the agreement, Dr. Smith has agreed to provide advisory services related to the Company’s clinical assets, capital markets, public company related issues and other matters as agreed to by the parties. The agreement expires in November. Dr. Smith is to receive total compensation of $90,000 and received 3,750 shares of common stock.   Lease Agreement –Monthly rental payments as of September 30, 2017 are $4,140 per month through January 2019. If the Company exercises the option to renew the lease, the monthly rental payments will further escalate by 3% per year during the additional term.   Minimum lease commitments at September 30, 2017 for the remaining term of the lease are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">Year ending September 30,</td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; padding-left: 20pt; line-height: 107%">2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">41,400</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%">Thereafter</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">41,400</td> <td style="line-height: 107%"> </td></tr> </table>   Lease expense charged to operations related to this agreement for the nine months ended September 30, 2017 and 2016 was $35,997 and $34,917, respectively.   License Agreement – The Company has a license agreement with a party related through a shareholder and former member of the board of directors. Under the agreement, the Company has the right to the exclusive use of certain patents pending and related technology in its medical devices and other products for an indefinite term. At September 30, 2017 and December 31, 2016, accrued royalties under this license agreement total $17,873, respectively.

Note 9 – Other Related Party Transactions   During the nine months ended September 30, 2017, the Company had a consulting agreement in place with one member and one former member (currently an officer of the Company) of its board of directors. The director and former director provide medical advisory services. The consulting agreement may be terminated by either the Company or by the consultant at any time and for any reason. During the three and nine months ended September 30, 2017, these individuals were paid a total of $73,761 and $153,681, respectively. During the three and nine months ended September 30, 2016, amounts paid for consulting agreements to former directors was $113,000 and $348,000, respectively.

Note 10 – Subsequent Events   The Company evaluated all subsequent events that occurred after the balance sheet date through November 14, 2017, the date its financial statements were available to be issued, and concluded there were no additional events or transactions occurring during this period that required recognition or disclosure in the financial statements.

Organization   ProLung, Inc. (formerly Fresh Medical Laboratories, Inc.) (the “Company”) is a Delaware corporation that was incorporated on November 22, 2004. The Company’s headquarters are located in Salt Lake City, Utah. The Company’s business is the development, marketing, and sale of precision predictive analytical medical devices specializing in lung cancer. The Company’s principal activities are primarily developing markets for its products, securing strategic alliances and obtaining financing.

Principles of Consolidation   During the year ended December 31, 2012, the Company formed a wholly-owned subsidiary, Hilltop Acquisition Corporation, Inc., which has had no activity since its inception and is included in the accompanying condensed consolidated financial statements from the date of its formation.

Basis of Presentation   The accompanying condensed consolidated financial statements have been prepared by management in accordance with rules and regulations promulgated by the U.S. Securities and Exchange Commission and therefore certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments necessary for them to be presented fairly, with those adjustments consisting only of normal recurring adjustments. These interim financial statements should be read in conjunction with the Company’s consolidated financial statements as of, and for the year ended, December 31, 2016 included in the Company’s Amendment No. 3 to the Annual Report on Form 10-K for the year ended December 31, 2016. The results of operations for the three and nine months ended September 30, 2017 may not be indicative of the results to be expected for the year ending December 31, 2017.   The Company has incurred losses since inception while pursuing the development of its primary predictive analytical medical device, and approval from the U.S. Food and Drug Administration (“FDA”) to market the device, while also developing markets outside the United States. The Company incurred net losses of $3.6 million and $2.1 million for the nine months ended September 30, 2017 and 2016, respectively. Cash used in operating activities was $3.4 million and $1.5 million for the nine months ended September 30, 2017 and 2016, respectively. Historically, operations have been funded primarily through the sale of equity or debt securities. Should management continue to fund operations at similar levels, additional equity or debt securities would need to be sold, or other financing arrangements made.   The Company has the ability to maintain current levels of spending, or reduce expenditures significantly if funding is not available. Additionally, should FDA approval be obtained, the Company could execute on an aggressive marketing plan that would require significant additional funding; however, this plan would not begin until funding is in place.

Basic and Diluted Loss Per Share   The Company computes basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. The Company computes diluted loss per share by dividing net loss by the sum of the weighted-average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of diluted loss per share does not assume exercise or conversion of securities that would have an anti-dilutive effect. As of September 30, 2017, and 2016, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Three and Nine Months Ended</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Warrants to purchase shares</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">1,205,623</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">177,901</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Stock options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">127,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,359</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Convertible debentures</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">275,509</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">201,155</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">205,212</td> <td style="line-height: 107%"> </td></tr> </table>

Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was amended with ASU No. 2015-14, ASU No. 2016-08, ASU No. 2016-10, ASU No. 2016-12 and ASU No. 2016-20. These new standards supersede all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The Company is evaluating the guidance but does not at this time expect it to have a material impact on the Company’s revenue recognition. However, the Company does expect to have significant changes to the footnote disclosures related to revenue recognition as a result of implementing these new standards. As the Company is an emerging growth company, this standard will be implemented effective January 1, 2019.   In February 2016, the FASB issued ASU No. 2016-02: Leases ASU 2016-02 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. ASU 2016-02 will be effective for the Company’s fiscal year beginning January 1, 2019, on a modified retrospective basis and earlier adoption is permitted. Management is currently evaluating the impact of the pending adoption of ASU 2016-02 on the Company’s consolidated financial statements.   In November 2016, the FASB issued an ASU amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt this ASU on January 1, 2018 and does not expect any accounting significance upon adoption.   In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. This Standard was issued to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt this ASU on January 1, 2018, since this standard is to be applied prospectively there will be no effect on prior financial statements and the Company does not currently have plans where this standard would be applicable.   In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II). Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down round features. Part II simply replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within Accounting Standards Codification (ASC) Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. This ASU is effective for public companies for the annual reporting periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of the standard may have on its consolidated financial statements and does not anticipate early adopting.   ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities was issued in August 2017. The amendments under ASU 2017-12 refine and expand hedge accounting requirements for both financial (e.g., interest rate) and commodity risks. Its provisions create more transparency around how economic results are presented, both on the face of the financial statements and in the footnotes. It also makes certain targeted improvements to simplify the application of hedge accounting guidance. ASU 2017-12 becomes effective for the Company in the first quarter of 2019. The Company is currently assessing the impact the adoption of this ASU will have on the consolidated financial statements.

As of September 30, 2017, and 2016, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Three and Nine Months Ended</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Warrants to purchase shares</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">1,205,623</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">177,901</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Stock options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">127,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,359</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Convertible debentures</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">275,509</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">201,155</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">205,212</td> <td style="line-height: 107%"> </td></tr> </table>

Inventory consists of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 107%">Raw materials</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">66,846</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">69,264</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Work in progress</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">11,222</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">31,185</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Finished goods</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">236,397</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">191,110</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Total inventory</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">314,465</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">291,559</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Less carrying value of inventory not deemed to be a current asset</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(314,465</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(291,559</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Inventory, included in current assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

Accrued liabilities consisted of the following at September 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 107%">Accrued interest</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">234,405</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accrued royalties</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">17,873</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">17,873</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accrued payroll and payroll taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">46,804</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">12,420</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total accrued liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">64,677</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">264,698</td> <td style="line-height: 107%"> </td></tr> </table>

Short and Long-term debt is summarized as follows   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Convertible debentures; unsecured; interest at 8.00% per annum; settled during 2017</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">1,257,050</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes payable; unsecured; interest at 8.00% per annum; due November 6, 2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Note payable secured by all the assets of the Company; interest at 15.00% per annum; settled during 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">189,389</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Related-party note payable; interest at 8%; settled during 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">105,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Unsecured note payable; interest at 10.00% per annum; settled during 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">32,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total long-term debt</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,790,370</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less:  current portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">137,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Long-term debt, net of current portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2,653,370</td> <td style="line-height: 107%"> </td></tr> </table>

A summary of the status of the Company’s restricted common stock grants as of September 30, 2017 and changes during the nine months then ended, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Restricted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Common</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Stock</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Common</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Grants</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Stock Price</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%">Balance at December 31, 2016</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 14%; text-align: right; line-height: 107%">109</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">4.00</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Awarded</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Vested</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(109</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.00</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Balance at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> </table>

Total stock-based compensation expense from all sources for the three and nine months ended September 30, 2017 and 2016, including stock-based compensation for the options and warrants discussed in Note 6 and 7, has been included in the unaudited condensed consolidated statements of operations as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Three Months Ended</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Nine Months Ended</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2016</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Research and development expense</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">79,915</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 12%; text-align: right; line-height: 107%">227,392</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Selling, general and administrative expense</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">261,153</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">30,854</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">385,013</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">104,849</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total share-based compensation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">261,153</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">110,769</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">385,013</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">332,241</td> <td style="line-height: 107%"> </td></tr> </table>

A summary of warrant activity for the nine months ended September 30, 2017 is presented below:     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Shares</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Value of</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Under</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Contractual</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Vested</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; line-height: 107%">Outstanding at December 31, 2016</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">430,938</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">7.04</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%"> 4.2 years </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">546,333</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">774,685</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">10.11</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> 2.2 years </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,205,623</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">9.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> 2.8 years </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1,230,829</td> <td style="line-height: 107%"> </td></tr> </table>

Minimum lease commitments at September 30, 2017 for the remaining term of the lease are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">Year ending September 30,</td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; padding-left: 20pt; line-height: 107%">2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">41,400</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%">Thereafter</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">41,400</td> <td style="line-height: 107%"> </td></tr> </table>

3000815

3861598

1355789

250

1355539

-55

55372

60000 5 59995 5000 3861598 6531567 545 6531022 544300

32000

121389

100000 Reverse Stock Split   On October 10, 2017, the Company’s Board of Directors approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effectuate a 1-for-8 reclassification, or reverse stock split, of the Company’s common stock, to be effective as of October 25, 2017. All share, option, warrant, per share, per option and per warrant amounts in the condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to the reverse stock split.

137000

1250

2020-09-30

2926

664452

53500

332241

433

121400

0.08

313419

217592

95827

P10Y

40202

472000

12.00

8.33

8.00

32813

8.53

P9Y10M25D

84651

82917

158567

165738

-664452 -664452

331513

Note 6 – Common Stock Options   Equity Incentive Plan   In April 2017 the Board of Directors, contingent on shareholder approval, approved the ProLung Inc. Stock Incentive Plan (the “Plan”). The shareholders approved the Plan in July 2017. The Plan authorizes the Board Compensation Committee to grant incentive stock options, non-incentive stock options, stock bonuses, restricted stock, and performance-based awards to directors, officers and employees and non-employee agents, consultants, advisers and independent contractors of the Company or any parent or subsidiary of the Company.   The total number of initial shares of Common Stock authorized for issuance under the Plan is 500,000 shares; the authorized shares will automatically increase on January 1st of each year, for ten consecutive years, commencing on January 1, 2018, by the lesser of (i) 40,000 shares of Common Stock (i.e., 8% of the shares of the shares originally authorized to be issued), or (ii) such number of shares of common stock (if any) the Board may earlier designate in writing. If the automatic increases are not limited by the Board, there will be 900,000 shares of common stock authorized under the Plan in January 1, 2027.   Issuance of Stock Options under the Plan   Board Option Grants   In August 2017, the Board’s Compensation Committee approved the issuance of 52,500 options to Directors of the Company at exercise prices ranging from $8.00 to $10.00 per option. One half of the options (26,250) vest immediately with the remaining half (26,250) vesting quarterly through August 2018. The fair value of these options was $5.97 per option or $313,419 and will be expensed over the relative vesting period. The fair value was computed using the Black Scholes method using the following weighted-average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; line-height: 107%">Expected life </td> <td style="width: 50%; text-align: right; line-height: 107%">5.12 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Exercise price</td> <td style="text-align: right; line-height: 107%">$8.33 </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected volatility</td> <td style="text-align: right; line-height: 107%">124%</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected dividends</td> <td style="text-align: right; line-height: 107%">None</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="text-align: right; line-height: 107%">1.84%</td></tr> </table>   The Company recorded an expense of $217,592 for the three and nine months ended September 30, 2017. The $95,827 remaining unrecognized expense will be recognized through April 2018.   CEO Stock Option Incentive   In an amendment to the employment agreement of the CEO executed March 29, 2017 the Company agreed to grant the CEO stock option incentives related to FDA approval. The stock option shall expire 10-years after the grant date and shall vest with respect to a number of options of Common Stock upon the receipt of FDA Approval (as defined below), with such number of options to be as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: center; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">150,000 options if FDA Approval is obtained on or before January 1, 2018;</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">112,500 options if FDA Approval is obtained after January 1, 2018 and on or before July 1, 2018;</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">75,000 options if FDA Approval is obtained after July 1, 2018 and on or before January 1, 2019;</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">37,500 options if FDA Approval is obtained after January 1, 2019 and on or before January 1, 2020.</td></tr> </table>   On August 9, 2017, the Compensation Committee of the Board of Directors granted the stock option described above at an exercise price of $8.00 per option. The Company considers these options to be performance based and August 9, 2017 to be the grant date. Solely for accounting purposes, the Company estimated the conditions for vesting will be met between July and December 2018. Based on this estimate, management also believes the most probable number of options to be issued will be 75,000. The Company valued these 75,000 options as of August 9, 2017 using the Black-Scholes Pricing Model using the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; line-height: 107%">Expected life </td> <td style="width: 50%; text-align: right; line-height: 107%">5.75 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Exercise price</td> <td style="text-align: right; line-height: 107%">$8.00 </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected volatility</td> <td style="text-align: right; line-height: 107%">124%</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected dividends</td> <td style="text-align: right; line-height: 107%">None</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="text-align: right; line-height: 107%">1.84%</td></tr> </table>   The resulting expense of $472,000 will be amortized over the estimated service period which will be the grant date through December 31, 2018. For the three and nine months ended September 30, 2017, $40,202 of expense has been recorded.   As of September 30, 2017, there are currently 372,500 options available for issuance under the Plan. As noted above we have issued performance based options to our CEO, whereby we could issue up to 150,000 options; which are included in the 37,500 options available for issuance under the Plan.   A summary of option activity for the nine months ended September 30, 2017 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Options</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Issued</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Contractual</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Value of</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Agreements</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at December 31, 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 107%">Issued</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">127,500</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">8.14</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">9.9 years</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">127,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">8.33</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9.9 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">32,813</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">8.53</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9.9 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

1-for-8 reclassification, or reverse stock split

430938

1205623

7.04 9.00 10.11 P2Y2M12D P2Y9M18D P4Y2M12D 546333 1230829

The fair value was computed using the Black Scholes method using the following weighted-average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; line-height: 107%">Expected life </td> <td style="width: 50%; text-align: right; line-height: 107%">5.12 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Exercise price</td> <td style="text-align: right; line-height: 107%">$8.33 </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected volatility</td> <td style="text-align: right; line-height: 107%">124%</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected dividends</td> <td style="text-align: right; line-height: 107%">None</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="text-align: right; line-height: 107%">1.84%</td></tr> </table>

The Company valued these 75,000 options as of August 9, 2017 using the Black-Scholes Pricing Model using the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; line-height: 107%">Expected life </td> <td style="width: 50%; text-align: right; line-height: 107%">5.75 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Exercise price</td> <td style="text-align: right; line-height: 107%">$8.00 </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected volatility</td> <td style="text-align: right; line-height: 107%">124%</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected dividends</td> <td style="text-align: right; line-height: 107%">None</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="text-align: right; line-height: 107%">1.84%</td></tr> </table>

41400

A summary of option activity for the nine months ended September 30, 2017 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Options</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Issued</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Contractual</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Value of</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Agreements</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life</td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="text-align: center; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at December 31, 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 107%">Issued</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">127,500</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">8.14</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">9.9 years</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Expired</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">127,500</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">8.33</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9.9 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">32,813</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">8.53</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9.9 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

The fair value was computed using the Black Scholes method using the following assumptions.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; line-height: 107%">Expected life </td> <td style="width: 50%; text-align: right; line-height: 107%">1.52 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Exercise price</td> <td style="text-align: right; line-height: 107%">$12.00 </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected volatility</td> <td style="text-align: right; line-height: 107%">107%</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Expected dividends</td> <td style="text-align: right; line-height: 107%">None</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="text-align: right; line-height: 107%">1.33%</td></tr> </table>

774685

3750

P2Y

EX-101.SCH 7 prl-20170930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Short and Long-term Debt link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Common Stock Options link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Common Stock Warrants link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Other Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Short and Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Common Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Common Stock Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Short and Long-term Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Short and Long-term Debt - Schedule of Short and Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Short and Long-term Debt - Schedule of Short and Long-term Debt (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Common Stock - Schedule of Restricted Common Stock Vested (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Common Stock - Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan(Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Common Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Common Stock Options - Schedule of Fair Value of Options Grants Using Black Scholes Method (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Common Stock Options - Summary of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Common Stock Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Common Stock Warrants - Schedule of Fair Value of Warrants Using Black Scholes Method (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Common Stock Warrants - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Other Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 prl-20170930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 prl-20170930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 prl-20170930_lab.xml XBRL LABEL FILE Short-term Debt, Type [Axis] Convertible Debentures [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Placement Agent Agreement [Member] Range [Axis] Maximum [Member] Debt Instrument [Axis] Convertible Notes [Member] Equity Components [Axis] Common Stock [Member] Note Payable to a Relative of an Executive Officer [Member] Other Notes Payable [Member] Related-party [Member] Sale of Stock [Axis] Private Placement [Member] Minimum [Member] Two Separate Placement Agents [Member] Award Type [Axis] Restricted Common Stock [Member] Income Statement Location [Axis] Research and Development Expense [Member] Selling, General and Administrative Expenses [Member] Warrants [Member] Consulting Agreement [Member] Title of Individual [Axis] Dr. Robin Smith [Member] Lease Agreement [Member] License Agreement [Member] Convertible Note Payable [Member] Secured Note Payable [Member] Unsecured Note Payable [Member] Warrant to Purchase Shares [Member] Non-Vested Shares [Member] Convertible Note [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Board Option Grants [Member] CEO Stock option Incentive [Member] Stock Option [Member] Related Party [Axis] Consultant [Member] Board of Directors [Member] Executive Officer [Member] Related-party [Member] Two Consultants [Member] Directors, Officers and Consultants [Member] Plan Name [Axis] Stock Incentive Plan [Member] Stock Option Incentive Plan [Member] Report Date [Axis] January 1, 2027 [Member] Directors [Member] Through August 2018 [Member] Employment Agreement [Member] U.S. Food and Drug Administration [Member] On or Before January 1, 2018 [Member] On or Before July 1, 2018 [Member] On or Before January 1, 2019 [Member] On or Before January 1, 2020 [Member] Through December 31, 2018 [Member] Chief Executive Officer [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Employees [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash Prepaid expenses Deferred offering costs Total Current Assets Inventory, noncurrent Property and equipment, net of accumulated depreciation Intangible assets, net of accumulated amortization Total Assets Liabilities and Stockholders' Equity (Deficit) Current Liabilities Accounts payable Accrued liabilities Related-party notes payable Current portion of long-term debt Total Current Liabilities Long-Term Liabilities Long-term debt, net of current portion Total Long-Term Liabilities Total Liabilities Stockholders' Equity (Deficit): Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding Common stock, $0.001 par value; 120,000,000 shares authorized; 3,861,598 shares and 3,000,815 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity (Deficit) Preferred Stock, par value Preferred Stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Common Stock, par value Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Income Statement [Abstract] Revenues: Revenue Total revenue Cost of revenue Gross loss Operating expenses: Research and development expense Selling, general and administrative expense Loss on disposal of property and equipment Total operating expenses Loss from operations Other income (expense): Interest expense Total other income (expense) Net loss Basic and diluted loss per share Weighted-average common shares outstanding, basic and diluted Statement [Table] Statement [Line Items] Balance beginning Balance beginning, shares Common stock issued upon conversion of debt and accrued interest Common stock issued upon conversion of debt and accrued interest, shares Common stock issued for cash and warrants, net of offering costs Common stock issued for cash and warrants, net of offering costs, shares Offering costs paid in cash Common stock issued to placement agent Common stock issued to placement agent, shares Common stock issued upon conversion of related party debt and accrued interest Common stock issued upon conversion of related party debt and accrued interest, shares Issuance of common stock to consultants for services Issuance of common stock to consultants for services, shares Stock-based compensation Rounding due to reverse stock split Net loss Balance ending Balance ending, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation Obsolete inventory Change in assets and liabilities: Inventory Prepaid expenses Accounts payable Accrued liabilities Net cash flows from operating activities Cash flows from investing activities: Payments for property and equipment Proceeds from sale of property and equipment Net cash flows from investing activities Cash flows from financing activities: Offering and deferred offering costs paid in cash Issuance of common stock and warrants for cash Payments on convertible debenture Proceeds from notes payable Payments on notes payable Proceeds from related party debt Payments on related party notes payable Net cash flows from financing activities Net increase (decrease) in cash Cash at beginning of period Cash at end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Supplemental disclosure of non-cash investing and financing activities: Conversion of convertible debt and interest Partial conversion of debt to equity Extinguishment of related-party note and interest with common stock Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies Inventory Disclosure [Abstract] Inventory Payables and Accruals [Abstract] Accrued Liabilities Debt Disclosure [Abstract] EX-101.PRE 11 prl-20170930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 10, 2017
Document And Entity Information
Entity Registrant Name	PROLUNG INC
Entity Central Index Key	0001541884
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		3,861,598
Trading Symbol	FRES
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current Assets
Cash	$ 1,783,449	$ 28,922
Prepaid expenses	20,981	8,831
Deferred offering costs	330,960
Total Current Assets	2,135,390	37,753
Inventory, noncurrent	314,465	291,559
Property and equipment, net of accumulated depreciation	84,651	82,917
Intangible assets, net of accumulated amortization	158,567	165,738
Total Assets	2,693,073	577,967
Current Liabilities
Accounts payable	194,957	358,477
Accrued liabilities	64,677	264,698
Related-party notes payable		105,000
Current portion of long-term debt		32,000
Total Current Liabilities	259,634	760,175
Long-Term Liabilities
Long-term debt, net of current portion	1,206,931	2,653,370
Total Long-Term Liabilities	1,206,931	2,653,370
Total Liabilities	1,466,565	3,413,545
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 120,000,000 shares authorized; 3,861,598 shares and 3,000,815 shares issued and outstanding, respectively	3,862	3,001
Additional paid-in capital	20,914,110	13,247,054
Accumulated deficit	(19,691,464)	(16,085,633)
Total Stockholders' Equity (Deficit)	1,226,508	(2,835,578)
Total Liabilities and Stockholders' Equity (Deficit)	$ 2,693,073	$ 577,967

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued
Preferred Stock, shares outstanding
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	120,000,000	120,000,000
Common Stock, shares issued	3,861,598	3,000,815
Common Stock, shares outstanding	3,861,598	3,000,815

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Revenue
Total revenue
Cost of revenue				10,193
Gross loss				(10,193)
Operating expenses:
Research and development expense	274,407	241,809	1,034,934	806,052
Selling, general and administrative expense	1,067,502	360,172	2,472,250	1,065,631
Loss on disposal of property and equipment	0	0	690
Total operating expenses	1,341,909	601,981	3,507,874	1,871,683
Loss from operations	(1,341,909)	(601,981)	(3,507,874)	(1,881,876)
Other income (expense):
Interest expense	(24,211)	(65,526)	(97,957)	(204,282)
Total other income (expense)	(24,211)	(65,526)	(97,957)	(204,282)
Net loss	$ (1,366,120)	$ (667,507)	$ (3,605,831)	$ (2,086,158)
Basic and diluted loss per share	$ (0.35)	$ (0.23)	$ (1.02)	$ (0.75)
Weighted-average common shares outstanding, basic and diluted	3,849,791	2,870,596	3,522,810	2,793,738

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance beginning at Dec. 31, 2016	$ 3,001	$ 13,247,054	$ (16,085,633)	$ (2,835,578)
Balance beginning, shares at Dec. 31, 2016	3,000,815
Common stock issued upon conversion of debt and accrued interest	$ 250	1,355,539		1,355,789
Common stock issued upon conversion of debt and accrued interest, shares	249,834
Common stock issued for cash and warrants, net of offering costs	$ 545	6,531,022		6,531,567
Common stock issued for cash and warrants, net of offering costs, shares	544,300
Offering costs paid in cash		(664,452)		(664,452)
Common stock issued to placement agent	$ 55	(55)
Common stock issued to placement agent, shares	55,372
Common stock issued upon conversion of related party debt and accrued interest	$ 5	59,995		60,000
Common stock issued upon conversion of related party debt and accrued interest, shares	5,000
Issuance of common stock to consultants for services	$ 6	53,494		53,500
Issuance of common stock to consultants for services, shares	6,250
Stock-based compensation		331,513		331,513
Rounding due to reverse stock split	27
Net loss			(3,605,831)	(3,605,831)
Balance ending at Sep. 30, 2017	$ 3,862	$ 20,914,110	$ (19,691,464)	$ 1,226,508
Balance ending, shares at Sep. 30, 2017	3,861,598

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (3,605,831)	$ (2,086,158)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	24,195	24,889
Stock-based compensation	385,013	332,241
Obsolete inventory		10,193
Loss on disposal of property and equipment	690
Change in assets and liabilities:
Inventory	(22,906)	(162,379)
Prepaid expenses	(12,150)	26,964
Accounts payable	(163,520)	230,306
Accrued liabilities	(32,282)	169,430
Net cash flows from operating activities	(3,426,791)	(1,454,514)
Cash flows from investing activities:
Payments for property and equipment	(19,842)
Proceeds from sale of property and equipment	394
Net cash flows from investing activities	(19,448)
Cash flows from financing activities:
Offering and deferred offering costs paid in cash	(995,412)
Issuance of common stock and warrants for cash	6,531,567	882,224
Payments on convertible debenture	(164,000)
Proceeds from notes payable		32,000
Payments on notes payable	(121,389)
Proceeds from related party debt		185,000
Payments on related party notes payable	(50,000)	(55,000)
Net cash flows from financing activities	5,200,766	1,044,224
Net increase (decrease) in cash	1,754,527	(410,290)
Cash at beginning of period	28,922	451,526
Cash at end of period	1,783,449	41,236
Supplemental disclosure of cash flow information:
Cash paid for interest	169,623	48,744
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible debt and interest	1,255,789	785,167
Partial conversion of debt to equity	100,000
Extinguishment of related-party note and interest with common stock	$ 60,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

Note 1 – Organization and Summary of Significant Accounting Policies

Organization

Principles of Consolidation

Reverse Stock Split

Basis of Presentation

Basic and Diluted Loss Per Share

	For the Three and Nine Months Ended
	September 30,
	2017		2016
Warrants to purchase shares		1,205,623		177,901
Stock options		127,500		-
Non-vested shares		-		1,359
Convertible debentures		-		275,509
Convertible notes		201,155		205,212

Recent Accounting Pronouncements

XML 19 R8.htm IDEA: XBRL DOCUMENT

Inventory

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Inventory

Note 2 – Inventory

Inventory consists of the following:

	September 30, 2017			December 31, 2016

Raw materials	$	66,846		$	69,264
Work in progress		11,222			31,185
Finished goods		236,397			191,110

Total inventory		314,465			291,559
Less carrying value of inventory not deemed to be a current asset		(314,465	)		(291,559	)

Inventory, included in current assets	$	-		$	-

XML 20 R9.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

9 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Accrued Liabilities

Note 3 – Accrued Liabilities

Accrued liabilities consisted of the following at September 30, 2017 and December 31, 2016:

	September 30, 2017		December 31, 2016
Accrued interest	$	-	$	234,405
Accrued royalties		17,873		17,873
Accrued payroll and payroll taxes		46,804		12,420

Total accrued liabilities	$	64,677	$	264,698

XML 21 R10.htm IDEA: XBRL DOCUMENT

Short and Long-term Debt

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Short and Long-term Debt

Note 4 –Short and Long-term Debt

Short and Long-term debt is summarized as follows

	September 30, 2017		December 31, 2016

Convertible debentures; unsecured; interest at 8.00% per annum; settled during 2017	$	-	$	1,257,050

Convertible notes payable; unsecured; interest at 8.00% per annum; due November 6, 2020		1,206,931		1,206,931

Note payable secured by all the assets of the Company; interest at 15.00% per annum; settled during 2017		-		189,389

Related-party note payable; interest at 8%; settled during 2017		-		105,000

Unsecured note payable; interest at 10.00% per annum; settled during 2017		-		32,000

Total long-term debt		1,206,931		2,790,370

Less: current portion		-		137,000

Long-term debt, net of current portion	$	1,206,931	$	2,653,370

Convertible Debentures

Convertible Notes Payable

Note Payable to a Relative of an Executive Officer

Other Notes Payable

Related-Party Note payable

XML 22 R11.htm IDEA: XBRL DOCUMENT

Common Stock

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Common Stock

Note 5 – Common Stock

Increase in Authorized Shares

Public Offering of Common Stock of the Company

Private Placement of Common Stock of the Company

During the nine months ended September 30, 2016, 82,380 shares were subscribed, conditions for the minimum offering were met, and the Company received net proceeds of $882,224 from the offering.

As of September 30, 2017, the adjusted maximum offering amount of $8.2 million was subscribed for and the offering was closed.

Common Stock Issued for Conversion of Convertible Debentures and Notes Payable

Common Stock Issued for Services

In addition, during the nine months ended September 30, 2016, the Company issued 2,496 shares of common stock with a total value of $29,651 to two consultants for services rendered.

A summary of the status of the Company’s restricted common stock grants as of September 30, 2017 and changes during the nine months then ended, is presented below:

	Restricted			Weighted
	Common			Average
	Stock			Common
	Grants			Stock Price

Balance at December 31, 2016		109		$	4.00
Awarded		-			-
Vested		(109	)		4.00

Balance at September 30, 2017		-

As of September 30, 2017, there are no longer any restricted common stock grants.

	For the Three Months Ended				For the Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016

Research and development expense	$	-	$	79,915	$	-	$	227,392
Selling, general and administrative expense		261,153		30,854		385,013		104,849

Total share-based compensation	$	261,153	$	110,769	$	385,013	$	332,241

XML 23 R12.htm IDEA: XBRL DOCUMENT

Common Stock Options

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common Stock Options

Note 6 – Common Stock Options

Equity Incentive Plan

Issuance of Stock Options under the Plan

Board Option Grants

Expected life	5.12 years
Exercise price	$8.33
Expected volatility	124%
Expected dividends	None
Risk-free interest rate	1.84%

The Company recorded an expense of $217,592 for the three and nine months ended September 30, 2017. The $95,827 remaining unrecognized expense will be recognized through April 2018.

CEO Stock Option Incentive

●	150,000 options if FDA Approval is obtained on or before January 1, 2018;

●	112,500 options if FDA Approval is obtained after January 1, 2018 and on or before July 1, 2018;

●	75,000 options if FDA Approval is obtained after July 1, 2018 and on or before January 1, 2019;

●	37,500 options if FDA Approval is obtained after January 1, 2019 and on or before January 1, 2020.

Expected life	5.75 years
Exercise price	$8.00
Expected volatility	124%
Expected dividends	None
Risk-free interest rate	1.84%

As of September 30, 2017, there are currently 372,500 options available for issuance under the Plan. As noted above we have issued performance based options to our CEO, whereby we could issue up to 150,000 options; which are included in the 37,500 options available for issuance under the Plan.

A summary of option activity for the nine months ended September 30, 2017 is presented below:

					Weighted
			Weighted		Average		Aggregate
	Options		Average		Remaining		Intrinsic
	Issued		Exercise		Contractual		Value of
	Agreements		Price		Life		Options

Outstanding at December 31, 2016		-	$	-		-	$	-
Issued		127,500		8.14		9.9 years		-
Exercised		-		-				-
Expired		-		-				-

Outstanding at September 30, 2017	$	127,500	$	8.33		9.9 years	$	-

Exercisable at September 30, 2017		32,813	$	8.53		9.9 years	$	-

XML 24 R13.htm IDEA: XBRL DOCUMENT

Common Stock Warrants

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common Stock Warrants

Note 7 – Common Stock Warrants

Expected life	1.52 years
Exercise price	$12.00
Expected volatility	107%
Expected dividends	None
Risk-free interest rate	1.33%

A summary of warrant activity for the nine months ended September 30, 2017 is presented below:

Weighted

Aggregate

Weighted

Average

Intrinsic

Shares

Average

Remaining

Value of

Under

Exercise

Contractual

Vested

Warrants

Price

Life

Warrants

Outstanding at December 31, 2016

430,938

7.04

4.2 years

546,333

Issued

774,685

10.11

2.2 years

Exercised

Expired

Outstanding at September 30, 2017

1,205,623

9.00

2.8 years

1,230,829

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8 – Commitments and Contingencies

Consulting Representation Agreement

Minimum lease commitments at September 30, 2017 for the remaining term of the lease are as follows:

Year ending September 30,
2018	$	41,400
Thereafter		-

Total	$	41,400

Lease expense charged to operations related to this agreement for the nine months ended September 30, 2017 and 2016 was $35,997 and $34,917, respectively.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Other Related Party Transactions

9 Months Ended

Sep. 30, 2017

Other Related Party Transactions

Note 9 – Other Related Party Transactions

XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

Note 10 – Subsequent Events

XML 28 R17.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Organization

Organization

Principles of Consolidation

Principles of Consolidation

Reverse Stock Split

Reverse Stock Split

Basis of Presentation

Basis of Presentation

Basic and Diluted Loss Per Share

Basic and Diluted Loss Per Share

	For the Three and Nine Months Ended
	September 30,
	2017		2016
Warrants to purchase shares		1,205,623		177,901
Stock options		127,500		-
Non-vested shares		-		1,359
Convertible debentures		-		275,509
Convertible notes		201,155		205,212

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 29 R18.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

As of September 30, 2017, and 2016, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:

	For the Three and Nine Months Ended
	September 30,
	2017		2016
Warrants to purchase shares		1,205,623		177,901
Stock options		127,500		-
Non-vested shares		-		1,359
Convertible debentures		-		275,509
Convertible notes		201,155		205,212

XML 30 R19.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following:

	September 30, 2017			December 31, 2016

Raw materials	$	66,846		$	69,264
Work in progress		11,222			31,185
Finished goods		236,397			191,110

Total inventory		314,465			291,559
Less carrying value of inventory not deemed to be a current asset		(314,465	)		(291,559	)

Inventory, included in current assets	$	-		$	-

XML 31 R20.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following at September 30, 2017 and December 31, 2016:

	September 30, 2017		December 31, 2016
Accrued interest	$	-	$	234,405
Accrued royalties		17,873		17,873
Accrued payroll and payroll taxes		46,804		12,420

Total accrued liabilities	$	64,677	$	264,698

XML 32 R21.htm IDEA: XBRL DOCUMENT

Short and Long-term Debt (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Schedule of Short and Long-term Debt

Short and Long-term debt is summarized as follows

	September 30, 2017		December 31, 2016

Convertible debentures; unsecured; interest at 8.00% per annum; settled during 2017	$	-	$	1,257,050

Convertible notes payable; unsecured; interest at 8.00% per annum; due November 6, 2020		1,206,931		1,206,931

Note payable secured by all the assets of the Company; interest at 15.00% per annum; settled during 2017		-		189,389

Related-party note payable; interest at 8%; settled during 2017		-		105,000

Unsecured note payable; interest at 10.00% per annum; settled during 2017		-		32,000

Total long-term debt		1,206,931		2,790,370

Less: current portion		-		137,000

Long-term debt, net of current portion	$	1,206,931	$	2,653,370

XML 33 R22.htm IDEA: XBRL DOCUMENT

Common Stock (Tables)

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Schedule of Restricted Common Stock Vested

A summary of the status of the Company’s restricted common stock grants as of September 30, 2017 and changes during the nine months then ended, is presented below:

	Restricted			Weighted
	Common			Average
	Stock			Common
	Grants			Stock Price

Balance at December 31, 2016		109		$	4.00
Awarded		-			-
Vested		(109	)		4.00

Balance at September 30, 2017		-

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan

	For the Three Months Ended				For the Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016

Research and development expense	$	-	$	79,915	$	-	$	227,392
Selling, general and administrative expense		261,153		30,854		385,013		104,849

Total share-based compensation	$	261,153	$	110,769	$	385,013	$	332,241

XML 34 R23.htm IDEA: XBRL DOCUMENT

Common Stock Options (Tables)

9 Months Ended

Sep. 30, 2017

Summary of Option Activity

A summary of option activity for the nine months ended September 30, 2017 is presented below:

					Weighted
			Weighted		Average		Aggregate
	Options		Average		Remaining		Intrinsic
	Issued		Exercise		Contractual		Value of
	Agreements		Price		Life		Options

Outstanding at December 31, 2016		-	$	-		-	$	-
Issued		127,500		8.14		9.9 years		-
Exercised		-		-				-
Expired		-		-				-

Outstanding at September 30, 2017	$	127,500	$	8.33		9.9 years	$	-

Exercisable at September 30, 2017		32,813	$	8.53		9.9 years	$	-

Board Option Grants [Member]

Schedule of Fair Value of Options Grants Using Black Scholes Method

The fair value was computed using the Black Scholes method using the following weighted-average assumptions:

Expected life	5.12 years
Exercise price	$8.33
Expected volatility	124%
Expected dividends	None
Risk-free interest rate	1.84%

CEO Stock option Incentive [Member]

Schedule of Fair Value of Options Grants Using Black Scholes Method

The Company valued these 75,000 options as of August 9, 2017 using the Black-Scholes Pricing Model using the following assumptions:

Expected life	5.75 years
Exercise price	$8.00
Expected volatility	124%
Expected dividends	None
Risk-free interest rate	1.84%

XML 35 R24.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Fair Value of Warrants Using Black Scholes Method

The fair value was computed using the Black Scholes method using the following assumptions.

Expected life	1.52 years
Exercise price	$12.00
Expected volatility	107%
Expected dividends	None
Risk-free interest rate	1.33%

Schedule of Warrant Activity

A summary of warrant activity for the nine months ended September 30, 2017 is presented below:

Weighted

Aggregate

Weighted

Average

Intrinsic

Shares

Average

Remaining

Value of

Under

Exercise

Contractual

Vested

Warrants

Price

Life

Warrants

Outstanding at December 31, 2016

430,938

7.04

4.2 years

546,333

Issued

774,685

10.11

2.2 years

Exercised

Expired

Outstanding at September 30, 2017

1,205,623

9.00

2.8 years

1,230,829

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Minimum Lease Commitments

Minimum lease commitments at September 30, 2017 for the remaining term of the lease are as follows:

Year ending September 30,
2018	$	41,400
Thereafter		-

Total	$	41,400

XML 37 R26.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Accounting Policies [Abstract]
Net losses	$ 1,366,120	$ 667,507	$ 3,605,831	$ 2,086,158
Reverse stock split			1-for-8 reclassification, or reverse stock split
Cash used in operating activities			$ 3,426,791	$ 1,454,514

XML 38 R27.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Warrant to Purchase Shares [Member]
Antidilutive securities excluded from computation of earnings per share	1,205,623	177,901	1,205,623	177,901
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share	127,500		52,500
Non-Vested Shares [Member]
Antidilutive securities excluded from computation of earnings per share		1,359		1,359
Convertible Debentures [Member]
Antidilutive securities excluded from computation of earnings per share		275,509		275,509
Convertible Note [Member]
Antidilutive securities excluded from computation of earnings per share	201,155	205,212	201,155	205,212

XML 39 R28.htm IDEA: XBRL DOCUMENT

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 66,846	$ 69,264
Work in progress	11,222	31,185
Finished goods	236,397	191,110
Total inventory	314,465	291,559
Less carrying value of inventory not deemed to be a current assets	(314,465)	291,559
Inventory, included in current assets

XML 40 R29.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued interest		$ 234,405
Accrued royalties	17,873	17,873
Accrued payroll and payroll taxes	46,804	12,420
Total accrued liabilities	$ 64,677	$ 264,698

XML 41 R30.htm IDEA: XBRL DOCUMENT

Short and Long-term Debt (Details Narrative) - USD ($)	9 Months Ended
Short and Long-term Debt (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Repayment of debentures	$ 164,000
Debt conversion of convertible debt		$ 717,950
Accrued interest			$ 234,405
Related-party [Member]
Repayment of debentures		55,000
Debt instrument interest amount		599
Debt principal amount		$ 160,000
Convertible Notes [Member]
Debt conversion price per share				$ 6.00
Debt principal amount				$ 1,206,931
Debt instrument interest rate				8.00%
Common stock trading and closes price per share				$ 28.00
Convertible Notes [Member] \| Common Stock [Member]
Debt conversion price per share				$ 6.00
Note Payable to a Relative of an Executive Officer [Member]
Debt conversion of convertible debt	100,000
Debt principal amount	89,389
Accrued interest	$ 39,071
Debt conversion of convertible shares issued	8,334
Warrant exercise price per share	$ 12.00
Number of warrant issued shares of common stock	8,334
Other Notes Payable [Member]
Repayment of debentures	$ 32,000
Debt instrument interest amount	1,185
Related-party [Member]
Repayment of debentures	105,000
Debt instrument interest amount	5,000
Debt conversion interest amount	60,000
Debt principal amount	55,000
Accrued interest	$ 50,000
Debt conversion of convertible shares issued	5,000
Warrant exercise price per share	$ 12.00
Number of warrant issued shares of common stock	5,000
Placement Agent Agreement [Member]
Debt conversion price per share	$ 6.48
Warrant exercise price per share	$ 5.20
Number of warrant issued shares of common stock	330,425
Placement Agent Agreement [Member] \| Maximum [Member]
Number of warrant issued shares of common stock	330,433
Warrant term	36 months
Convertible Debentures [Member]
Repayment of debentures	$ 164,000
Debt instrument interest amount	25,700
Debt conversion of convertible debt	1,093,050
Debt conversion interest amount	$ 162,739
Debt conversion price per share	$ 5.20
Debt conversion of convertible shares issued	241,500
Debt instrument interest rate	8.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Short and Long-term Debt - Schedule of Short and Long-term Debt (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Convertible debentures; unsecured; interest at 8.00% per annum; settled during 2017		$ 1,257,050
Convertible notes payable; unsecured; interest at 8.00% per annum; due November 6, 2020	1,206,931	1,206,931
Note payable secured by all the assets of the Company; interest at 15.00% per annum; settled during 2017		189,389
Related-party note payable; interest at 8%; settled during 2017		105,000
Unsecured note payable; interest at 10.00% per annum; settled during 2017		32,000
Total long-term debt	1,206,931	2,790,370
Less: current portion		137,000
Long-term debt, net of current portion	$ 1,206,931	$ 2,653,370

XML 43 R32.htm IDEA: XBRL DOCUMENT

Short and Long-term Debt - Schedule of Short and Long-term Debt (Details) (Parenthetical)	9 Months Ended
	Sep. 30, 2017
Convertible Debentures [Member]
Debt interest percentage	8.00%
Debt instrument term description	during 2017
Convertible Note Payable [Member]
Debt interest percentage	8.00%
Debt instrument term description	due November 6, 2020
Secured Note Payable [Member]
Debt interest percentage	15.00%
Debt instrument term description	during 2017
Related-party [Member]
Debt interest percentage	8.00%
Debt instrument term description	during 2017
Unsecured Note Payable [Member]
Debt interest percentage	10.00%
Debt instrument term description	during 2017

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 44 R33.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
Common Stock (Details Narrative) - USD ($)	Feb. 28, 2017	Sep. 30, 2017	Sep. 30, 2016	Jul. 30, 2017	Dec. 31, 2016
Deferred offering costs		$ 330,960
Number of units subscribed			82,380
Common stock shares issued		3,861,598			3,000,815
Proceeds from net offering costs			$ 882,224
Debt conversion of convertible debt			717,950
Accrued interest			$ 67,217
Number of common stock shares issued for conversion			150,994
Common stock issued price per share			$ 5.20
Number of common stock shares issued for services, value		$ 53,500
Convertible Debentures [Member]
Debt conversion of convertible debt		1,093,050
Accrued interest		$ 162,739
Debt conversion price per share		$ 5.20
Debt conversion of convertible shares issued		241,500
Convertible Debentures [Member] \| Related-party [Member]
Debt conversion of convertible debt		$ 55,000
Accrued interest		$ 5,000
Debt conversion price per share		$ 12.00
Debt conversion of convertible shares issued		5,000
Executive Officer [Member] \| Convertible Debentures [Member]
Debt conversion of convertible debt		$ 100,000
Debt conversion price per share		$ 12.00
Debt conversion of convertible shares issued		8,334
Two Consultants [Member]
Number of common stock shares issued for services		2,496
Number of common stock shares issued for services, value		$ 29,651
Directors, Officers and Consultants [Member]
Recognized stock based compensation		53,500	$ 332,241
Amortization of Deferred compensation		$ 433	121,400
Private Placement [Member]
Number of units subscribed		41,667
Two Separate Placement Agents [Member]
Commission fees		$ 826,146
Common stock shares issued		67,258
Proceeds from net offering costs		$ 6,531,567
Payment for net offering costs		$ 664,452
Maximum [Member]
Excess stock, shares authorized				40,000,000
Number of common stock units offered value			$ 8,200,000
Maximum [Member] \| Private Placement [Member]
Number of common stock units offered		437,500
Common stock price per share		$ 1.50
Number of common stock units offered value		$ 5,250,000
Maximum [Member] \| Private Placement [Member] \| Board of Directors [Member]
Number of common stock units offered	682,669
Number of common stock units offered value	$ 8,200,000
Minimum [Member]
Excess stock, shares authorized				120,000,000
Minimum [Member] \| Private Placement [Member]
Number of common stock units offered		41,667
Common stock price per share		$ 12.00
Number of common stock units offered value		$ 500,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Common Stock - Schedule of Restricted Common Stock Vested (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Restricted Common Stock Grants Awarded	127,500
Weighted Average Common Stock Price Awarded	$ 2.34
Weighted Average Common Stock Price Vested	$ 6.32	$ 6.08
Restricted Common Stock [Member]
Restricted Common Stock Grants Beginning Balance	109
Restricted Common Stock Grants Awarded
Restricted Common Stock Grants Vested	(109)
Restricted Common Stock Grants Ending Balance
Weighted Average Common Stock Price Beginning Balance	$ 4.00
Weighted Average Common Stock Price Awarded
Weighted Average Common Stock Price Vested	4.00
Weighted Average Common Stock Price Ending Balance

XML 46 R35.htm IDEA: XBRL DOCUMENT

Common Stock - Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan(Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation	$ 261,153	$ 110,769	$ 385,013	$ 332,241
Research and Development Expense [Member]
Stock-based compensation		79,915		227,392
Selling, General and Administrative Expenses [Member]
Stock-based compensation	$ 261,153	$ 30,854	$ 385,013	$ 104,849

XML 47 R36.htm IDEA: XBRL DOCUMENT

Common Stock Options (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended	9 Months Ended
Common Stock Options (Details Narrative) - USD ($)	Aug. 09, 2017	Mar. 29, 2017	Apr. 30, 2017	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Common stock shares authorized				120,000,000	120,000,000	120,000,000
Common stock shares issued				3,861,598	3,861,598	3,000,815
Number of option granted					127,500
Option exercise price per share					$ 8.14
Vested price per share					$ 2.34
Stock option expenses				$ 217,592	$ 217,592
Amortization related cost				40,202	40,202
Employment Agreement [Member]
Stock option expire year		10 years
Directors [Member]
Number of option granted			52,500
Number of option vested			26,250
Vested price per share			$ 5.97
Fair value of vested			$ 313,419
Directors [Member] \| Minimum [Member]
Option exercise price per share			$ 8.00
Directors [Member] \| Maximum [Member]
Option exercise price per share			$ 10.00
Board of Directors [Member]
Number of option granted	75,000
Option exercise price per share	$ 8.00
Through August 2018 [Member]
Unrecognized expense				$ 95,827	$ 95,827
Through August 2018 [Member] \| Directors [Member]
Number of option vested			26,250
On or Before January 1, 2018 [Member] \| Employment Agreement [Member] \| U.S. Food and Drug Administration [Member]
Number of option granted		150,000
On or Before July 1, 2018 [Member] \| Employment Agreement [Member] \| U.S. Food and Drug Administration [Member]
Number of option granted		112,500
On or Before January 1, 2019 [Member] \| Employment Agreement [Member] \| U.S. Food and Drug Administration [Member]
Number of option granted		75,000
On or Before January 1, 2020 [Member] \| Employment Agreement [Member] \| U.S. Food and Drug Administration [Member]
Number of option granted		37,500
Through December 31, 2018 [Member]
Amortization related cost	$ 472,000
Stock Incentive Plan [Member]
Common stock shares authorized			500,000
Common stock shares issued			40,000
Common stock shares issued percentage			8.00%
Stock Option Incentive Plan [Member]
Number of option granted					372,500
Stock Option Incentive Plan [Member] \| Chief Executive Officer [Member] \| Maximum [Member]
Number of option granted					150,000
Stock Option Incentive Plan [Member] \| January 1, 2027 [Member]
Common stock shares authorized			900,000

XML 48 R37.htm IDEA: XBRL DOCUMENT

Common Stock Options - Schedule of Fair Value of Options Grants Using Black Scholes Method (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Expected life	4 years 6 months	4 years 6 months
Expected volatility	122.00%	124.00%
Expected dividends	0.00%	0.00%
Risk-free interest rate	1.84%	1.33%
Board Option Grants [Member]
Expected life	5 years 1 month 13 days
Exercise price	$ 8.33
Expected volatility	124.00%
Expected dividends	0.00%
Risk-free interest rate	1.84%
CEO Stock option Incentive [Member]
Expected life	5 years 9 months
Exercise price	$ 8.00
Expected volatility	124.00%
Expected dividends	0.00%
Risk-free interest rate	1.84%

XML 49 R38.htm IDEA: XBRL DOCUMENT

Common Stock Options - Summary of Option Activity (Details)	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Option issued agreements outstanding \| shares
Option issued agreements issued \| shares	127,500
Option issued agreements exercised \| shares
Option issued agreements expired \| shares
Option issued agreements outstanding \| shares	127,500
Option issued agreements exercisable \| shares	32,813
Weighted average exercise price outstanding \| $ / shares
Weighted average exercise price issued \| $ / shares	8.14
Weighted average exercise price exercised \| $ / shares
Weighted average exercise price expired \| $ / shares
Weighted average exercise price outstanding \| $ / shares	8.14
Weighted average exercise price exercisable \| $ / shares	$ 8.53
Weighted average remaining contractual life outstanding	9 years 10 months 25 days
Weighted average remaining contractual life issued	9 years 10 months 25 days
Weighted average remaining contractual life in years exercisable	9 years 10 months 25 days
Aggregate intrinsic value outstanding \| $
Aggregate intrinsic value exercisable \| $

XML 50 R39.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Common Stock Warrants (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair value of warrant vested price per share			$ 6.32	$ 6.08
Risk-free interest rate			1.84%	1.33%
Expected volatility			122.00%	124.00%
Expected life			4 years 6 months	4 years 6 months
Expected dividend yield			0.00%	0.00%
Share based compensation	$ 261,153	$ 110,769	$ 385,013	$ 332,241
Intrinsic value per share			$ 7.28
Warrants expiration date			Sep. 30, 2020
Fair value of warrants			$ 2,926
Fair value of warrants exercise price			$ 2.34
Consultant [Member]
Warrants issued	1,250		1,250
Exercise price of warrants	$ 12		$ 12
Warrants [Member]
Risk-free interest rate			1.33%
Expected volatility			107.00%
Expected life			4 years 2 months 12 days
Expected dividend yield			0.00%
Share based compensation	$ 35,446	$ 33,912	$ 70,360	$ 67,945

XML 51 R40.htm IDEA: XBRL DOCUMENT

Common Stock Warrants - Schedule of Fair Value of Warrants Using Black Scholes Method (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Expected life	4 years 6 months	4 years 6 months
Expected volatility	122.00%	124.00%
Expected dividends	0.00%	0.00%
Risk-free interest rate	1.84%	1.33%
Warrants [Member]
Expected life	4 years 2 months 12 days
Exercise price	$ 12.00
Expected volatility	107.00%
Expected dividends	0.00%
Risk-free interest rate	1.33%

XML 52 R41.htm IDEA: XBRL DOCUMENT

Common Stock Warrants - Schedule of Warrant Activity (Details) - Warrants [Member]	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Shares Outstanding, Beginning Balance \| shares	430,938
Shares, Issued \| shares	774,685
Shares, Exercised \| shares
Shares, Expired \| shares
Shares Outstanding, Ending Balance \| shares	1,205,623
Weighted-Average Exercise Price, Outstanding Beginning Balance \| $ / shares	$ 7.04
Weighted-Average Exercise Price, Issued \| $ / shares	10.11
Weighted-Average Exercise Price, Exercised \| $ / shares
Weighted-Average Exercise Price, Expired \| $ / shares
Weighted-Average Exercise Price, Outstanding Ending Balance \| $ / shares	$ 9.00
Weighted-Average Remaining Contractual Terms (Years), Outstanding Beginning Balance	4 years 2 months 12 days
Weighted-Average Remaining Contractual Terms (Years), Issued	2 years 2 months 12 days
Weighted-Average Remaining Contractual Terms (Years), Outstanding Ending Balance	2 years 9 months 18 days
Aggregate Intrinsic Value Shares Outstanding Beginning \| $	$ 546,333
Aggregate Intrinsic Value Shares Outstanding Ending \| $	$ 1,230,829

XML 53 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 28, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Percentage of increase in lease rental payment		3.00%
Operating lease expense		$ 35,997	$ 34,917
Consulting Agreement [Member] \| Dr. Robin Smith [Member]
Agreement term	9 months
Officers Compensation	$ 90,000
Number of common stock shares issued for compensation	3,750
Lease Agreement [Member]
Monthly rental payment		4,140
License Agreement [Member]
Accrued royalties		$ 17,873		$ 17,873

XML 54 R43.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Minimum Lease Commitments (Details)	Sep. 30, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 41,400
Thereafter
Total	$ 41,400

XML 55 R44.htm IDEA: XBRL DOCUMENT

Other Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Related Party Transactions [Abstract]
Other related party transaction amount	$ 73,761	$ 113,000	$ 153,681	$ 348,000

XML 56 R45.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - $ / shares		9 Months Ended
Subsequent Events (Details Narrative) - $ / shares	Nov. 10, 2017	Sep. 30, 2017
Number of option granted		127,500
Option exercise price per share		$ 8.14
Subsequent Event [Member] \| Employees [Member]
Number of option granted	204,250
Option exercise price per share	$ 8.00
Options vesting term	2 years

EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 122 221 1 false 54 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://prolunginc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://prolunginc.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://prolunginc.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://prolunginc.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://prolunginc.com/role/StatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://prolunginc.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Inventory Sheet http://prolunginc.com/role/Inventory Inventory Notes 8 false false R9.htm 00000009 - Disclosure - Accrued Liabilities Sheet http://prolunginc.com/role/AccruedLiabilities Accrued Liabilities Notes 9 false false R10.htm 00000010 - Disclosure - Short and Long-term Debt Sheet http://prolunginc.com/role/ShortAndLong-termDebt Short and Long-term Debt Notes 10 false false R11.htm 00000011 - Disclosure - Common Stock Sheet http://prolunginc.com/role/CommonStock Common Stock Notes 11 false false R12.htm 00000012 - Disclosure - Common Stock Options Sheet http://prolunginc.com/role/CommonStockOptions Common Stock Options Notes 12 false false R13.htm 00000013 - Disclosure - Common Stock Warrants Sheet http://prolunginc.com/role/CommonStockWarrants Common Stock Warrants Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://prolunginc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Other Related Party Transactions Sheet http://prolunginc.com/role/OtherRelatedPartyTransactions Other Related Party Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://prolunginc.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Inventory (Tables) Sheet http://prolunginc.com/role/InventoryTables Inventory (Tables) Tables http://prolunginc.com/role/Inventory 19 false false R20.htm 00000020 - Disclosure - Accrued Liabilities (Tables) Sheet http://prolunginc.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://prolunginc.com/role/AccruedLiabilities 20 false false R21.htm 00000021 - Disclosure - Short and Long-term Debt (Tables) Sheet http://prolunginc.com/role/ShortAndLong-termDebtTables Short and Long-term Debt (Tables) Tables http://prolunginc.com/role/ShortAndLong-termDebt 21 false false R22.htm 00000022 - Disclosure - Common Stock (Tables) Sheet http://prolunginc.com/role/CommonStockTables Common Stock (Tables) Tables http://prolunginc.com/role/CommonStock 22 false false R23.htm 00000023 - Disclosure - Common Stock Options (Tables) Sheet http://prolunginc.com/role/CommonStockOptionsTables Common Stock Options (Tables) Tables http://prolunginc.com/role/CommonStockOptions 23 false false R24.htm 00000024 - Disclosure - Common Stock Warrants (Tables) Sheet http://prolunginc.com/role/CommonStockWarrantsTables Common Stock Warrants (Tables) Tables http://prolunginc.com/role/CommonStockWarrants 24 false false R25.htm 00000025 - Disclosure - Commitments and Contingencies (Tables) Sheet http://prolunginc.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://prolunginc.com/role/CommitmentsAndContingencies 25 false false R26.htm 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Details) Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Details) Details 27 false false R28.htm 00000028 - Disclosure - Inventory - Schedule of Inventory (Details) Sheet http://prolunginc.com/role/Inventory-ScheduleOfInventoryDetails Inventory - Schedule of Inventory (Details) Details 28 false false R29.htm 00000029 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://prolunginc.com/role/AccruedLiabilities-ScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 29 false false R30.htm 00000030 - Disclosure - Short and Long-term Debt (Details Narrative) Sheet http://prolunginc.com/role/ShortAndLong-termDebtDetailsNarrative Short and Long-term Debt (Details Narrative) Details http://prolunginc.com/role/ShortAndLong-termDebtTables 30 false false R31.htm 00000031 - Disclosure - Short and Long-term Debt - Schedule of Short and Long-term Debt (Details) Sheet http://prolunginc.com/role/ShortAndLong-termDebt-ScheduleOfShortAndLong-termDebtDetails Short and Long-term Debt - Schedule of Short and Long-term Debt (Details) Details 31 false false R32.htm 00000032 - Disclosure - Short and Long-term Debt - Schedule of Short and Long-term Debt (Details) (Parenthetical) Sheet http://prolunginc.com/role/ShortAndLong-termDebt-ScheduleOfShortAndLong-termDebtDetailsParenthetical Short and Long-term Debt - Schedule of Short and Long-term Debt (Details) (Parenthetical) Details 32 false false R33.htm 00000033 - Disclosure - Common Stock (Details Narrative) Sheet http://prolunginc.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://prolunginc.com/role/CommonStockTables 33 false false R34.htm 00000034 - Disclosure - Common Stock - Schedule of Restricted Common Stock Vested (Details) Sheet http://prolunginc.com/role/CommonStock-ScheduleOfRestrictedCommonStockVestedDetails Common Stock - Schedule of Restricted Common Stock Vested (Details) Details 34 false false R35.htm 00000035 - Disclosure - Common Stock - Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan(Details) Sheet http://prolunginc.com/role/CommonStock-ScheduleOfCompensationCostForShare-basedPaymentArrangementsAllocationOfShare-basedCompensationCostsByPlandetails Common Stock - Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan(Details) Details 35 false false R36.htm 00000036 - Disclosure - Common Stock Options (Details Narrative) Sheet http://prolunginc.com/role/CommonStockOptionsDetailsNarrative Common Stock Options (Details Narrative) Details http://prolunginc.com/role/CommonStockOptionsTables 36 false false R37.htm 00000037 - Disclosure - Common Stock Options - Schedule of Fair Value of Options Grants Using Black Scholes Method (Details) Sheet http://prolunginc.com/role/CommonStockOptions-ScheduleOfFairValueOfOptionsGrantsUsingBlackScholesMethodDetails Common Stock Options - Schedule of Fair Value of Options Grants Using Black Scholes Method (Details) Details 37 false false R38.htm 00000038 - Disclosure - Common Stock Options - Summary of Option Activity (Details) Sheet http://prolunginc.com/role/CommonStockOptions-SummaryOfOptionActivityDetails Common Stock Options - Summary of Option Activity (Details) Details 38 false false R39.htm 00000039 - Disclosure - Common Stock Warrants (Details Narrative) Sheet http://prolunginc.com/role/CommonStockWarrantsDetailsNarrative Common Stock Warrants (Details Narrative) Details http://prolunginc.com/role/CommonStockWarrantsTables 39 false false R40.htm 00000040 - Disclosure - Common Stock Warrants - Schedule of Fair Value of Warrants Using Black Scholes Method (Details) Sheet http://prolunginc.com/role/CommonStockWarrants-ScheduleOfFairValueOfWarrantsUsingBlackScholesMethodDetails Common Stock Warrants - Schedule of Fair Value of Warrants Using Black Scholes Method (Details) Details 40 false false R41.htm 00000041 - Disclosure - Common Stock Warrants - Schedule of Warrant Activity (Details) Sheet http://prolunginc.com/role/CommonStockWarrants-ScheduleOfWarrantActivityDetails Common Stock Warrants - Schedule of Warrant Activity (Details) Details 41 false false R42.htm 00000042 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://prolunginc.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://prolunginc.com/role/CommitmentsAndContingenciesTables 42 false false R43.htm 00000043 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Commitments (Details) Sheet http://prolunginc.com/role/CommitmentsAndContingencies-ScheduleOfMinimumLeaseCommitmentsDetails Commitments and Contingencies - Schedule of Minimum Lease Commitments (Details) Details 43 false false R44.htm 00000044 - Disclosure - Other Related Party Transactions (Details Narrative) Sheet http://prolunginc.com/role/OtherRelatedPartyTransactionsDetailsNarrative Other Related Party Transactions (Details Narrative) Details http://prolunginc.com/role/OtherRelatedPartyTransactions 44 false false R45.htm 00000045 - Disclosure - Subsequent Events (Details Narrative) Sheet http://prolunginc.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://prolunginc.com/role/SubsequentEvents 45 false false All Reports Book All Reports prl-20170930.xml prl-20170930.xsd prl-20170930_cal.xml prl-20170930_def.xml prl-20170930_lab.xml prl-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 63 0001493152-17-013096-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-013096-xbrl.zip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